tmo fasb org gaap othernonoperatingincomeexpensehttp fasb org gaap othernonoperatingincomeexpensehttp fasb org gaap othernonoperatingincomeexpensehttp fasb org gaap othernonoperatingincomeexpensehttp fasb org gaap othernonoperatingincomeexpenseinvestments measured net asset value per share equivalent practical expedient classified the fair value hierarchy http fasb org gaap longtermdebtandcapitalleaseobligationshttp fasb org gaap longtermdebtandcapitalleaseobligationshttp fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherliabilitiescurrenthttp fasb org gaap otherliabilitiescurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap otherliabilitiescurrent http fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap sellinggeneralandadministrativeexpensehttp fasb org gaap sellinggeneralandadministrativeexpensehttp fasb org gaap otherassetscurrent http fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherassetscurrenthttp fasb org gaap gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap retainedearningsmembersrt gaap accumulatedothercomprehensiveincomemembersrt gaap parentmembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap productmemberus gaap laboratoryproductsandservicesmemberus gaap gaap productmembertmo laboratoryproductsandservicesmemberus gaap gaap changeinaccountingprincipleothermembertmo gaap productmemberus gaap changeinaccountingprincipleothermembertmo gaap buildingandbuildingimprovementsmembersrt gaap buildingandbuildingimprovementsmembersrt gaap machineryandequipmentmembersrt gaap machineryandequipmentmembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap subsequenteventmembertmo gaap subsequenteventmembertmo gaap gaap gaap customerrelationshipsmembertmo peprotechincmemberus gaap europeanviralvectormanufacturingbusinessmemberus gaap mesabiotechmemberus gaap gaap customerrelationshipsmembertmo gaap seriesofindividuallyimmaterialbusinessacquisitionsmemberus gaap gaap developedtechnologyrightsmembertmo gaap developedtechnologyrightsmembertmo gaap developedtechnologyrightsmembertmo gaap developedtechnologyrightsmembertmo gaap developedtechnologyrightsmembertmo gaap developedtechnologyrightsmemberus gaap gaap tradenamesmembertmo gaap tradenamesmembertmo europeanviralvectormanufacturingbusinessmemberus gaap mesabiotechmemberus gaap gaap tradenamesmembertmo gaap seriesofindividuallyimmaterialbusinessacquisitionsmemberus gaap gaap orderorproductionbacklogmembertmo gaap gaap gaap gaap ppdincmemberus gaap ppdincmemberus gaap gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap operatingsegmentsmembertmo gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap interestrateswapmemberus gaap otherexpensememberus gaap gaap employeestockoptionmembersrt maximummemberus gaap gaap gaap gaap restrictedstockunitsrsumembersrt gaap restrictedstockunitsrsumembersrt gaap gaap usus gaap usus gaap gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap usus gaap gaap foreignplanmemberus gaap usus gaap usus gaap gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap usus gaap gaap gaap usequityfundsmembercountry usus gaap usus gaap pensionplansdefinedbenefitmembertmo gaap fixedincomefundsmembercountry usus gaap minimummemberus gaap equityfundsmemberus gaap foreignplanmemberus gaap maximummemberus gaap equityfundsmemberus gaap foreignplanmemberus gaap gaap fixedincomefundsmembersrt minimummemberus gaap foreignplanmemberus gaap maximummemberus gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap minimummemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo maximummemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap definedbenefitplanderivativemembersrt minimummemberus gaap foreignplanmemberus gaap gaap definedbenefitplanderivativemembersrt maximummemberus gaap foreignplanmemberus gaap gaap usequityfundsmembercountry usus gaap usequityfundsmembercountry usus gaap gaap gaap usequityfundsmembercountry usus gaap gaap fairvaluemeasuredatnetassetvaluepersharemembertmo usequityfundsmembercountry usus gaap gaap usus gaap pensionplansdefinedbenefitmembertmo usus gaap gaap pensionplansdefinedbenefitmembertmo gaap usus gaap pensionplansdefinedbenefitmembertmo gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usus gaap pensionplansdefinedbenefitmembertmo gaap fixedincomefundsmemberus gaap usus gaap gaap fixedincomefundsmembercountry usus gaap gaap gaap gaap fixedincomefundsmembercountry usus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap fixedincomefundsmembercountry usus gaap gaap moneymarketfundsmembercountry usus gaap gaap moneymarketfundsmemberus gaap usus gaap gaap moneymarketfundsmembercountry usus gaap gaap gaap moneymarketfundsmemberus gaap usus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap moneymarketfundsmembercountry usus gaap gaap usus gaap usus gaap gaap gaap usus gaap gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usus gaap gaap equityfundsmemberus gaap foreignplanmemberus gaap gaap equityfundsmemberus gaap gaap foreignplanmemberus gaap gaap equityfundsmemberus gaap gaap foreignplanmemberus gaap gaap gaap equityfundsmemberus gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap equityfundsmemberus gaap foreignplanmemberus gaap gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap gaap fixedincomefundsmemberus gaap gaap foreignplanmemberus gaap gaap fixedincomefundsmemberus gaap gaap foreignplanmemberus gaap gaap gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap definedbenefitplanderivativememberus gaap foreignplanmemberus gaap gaap definedbenefitplanderivativememberus gaap gaap foreignplanmemberus gaap gaap definedbenefitplanderivativememberus gaap gaap foreignplanmemberus gaap gaap definedbenefitplanderivativememberus gaap gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap definedbenefitplanderivativememberus gaap foreignplanmemberus gaap insurancecontractsmemberus gaap foreignplanmemberus gaap insurancecontractsmemberus gaap gaap foreignplanmemberus gaap insurancecontractsmemberus gaap gaap foreignplanmemberus gaap gaap insurancecontractsmemberus gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharemembertmo insurancecontractsmemberus gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap gaap gaap foreignplanmemberus gaap gaap gaap foreignplanmemberus gaap gaap gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap usequityfundsmembercountry usus gaap gaap usequityfundsmembercountry usus gaap usequityfundsmembercountry usus gaap gaap gaap usequityfundsmembercountry usus gaap gaap fairvaluemeasuredatnetassetvaluepersharemembertmo usequityfundsmembercountry usus gaap usus gaap pensionplansdefinedbenefitmembertmo gaap usus gaap pensionplansdefinedbenefitmembertmo usus gaap gaap pensionplansdefinedbenefitmembertmo gaap usus gaap pensionplansdefinedbenefitmembertmo gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usus gaap pensionplansdefinedbenefitmembertmo gaap fixedincomefundsmembercountry usus gaap gaap fixedincomefundsmemberus gaap usus gaap gaap fixedincomefundsmembercountry usus gaap gaap gaap gaap fixedincomefundsmembercountry usus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap fixedincomefundsmembercountry usus gaap gaap moneymarketfundsmembercountry usus gaap gaap moneymarketfundsmemberus gaap usus gaap gaap moneymarketfundsmembercountry usus gaap gaap gaap moneymarketfundsmemberus gaap usus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap moneymarketfundsmembercountry usus gaap gaap usus gaap usus gaap gaap gaap usus gaap gaap fairvaluemeasuredatnetassetvaluepersharemembercountry usus gaap gaap equityfundsmemberus gaap foreignplanmemberus gaap gaap equityfundsmemberus gaap gaap foreignplanmemberus gaap gaap equityfundsmemberus gaap gaap foreignplanmemberus gaap gaap gaap equityfundsmemberus gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap equityfundsmemberus gaap foreignplanmemberus gaap gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap gaap fixedincomefundsmemberus gaap gaap foreignplanmemberus gaap gaap fixedincomefundsmemberus gaap gaap foreignplanmemberus gaap gaap gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap fixedincomefundsmemberus gaap foreignplanmemberus gaap gaap hedgefundsmemberus gaap foreignplanmemberus gaap gaap hedgefundsmemberus gaap gaap foreignplanmemberus gaap gaap hedgefundsmemberus gaap gaap foreignplanmemberus gaap gaap gaap hedgefundsmemberus gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap hedgefundsmemberus gaap foreignplanmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembertmo gaap definedbenefitplanderivativememberus gaap foreignplanmemberus gaap gaap definedbenefitplanderivativememberus gaap gaap foreignplanmemberus gaap gaap definedbenefitplanderivativememberus gaap gaap foreignplanmemberus gaap gaap definedbenefitplanderivativememberus gaap gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap definedbenefitplanderivativememberus gaap foreignplanmemberus gaap alternativeinvestmentsmemberus gaap foreignplanmemberus gaap alternativeinvestmentsmemberus gaap gaap foreignplanmemberus gaap alternativeinvestmentsmemberus gaap gaap foreignplanmemberus gaap gaap alternativeinvestmentsmemberus gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharemembertmo alternativeinvestmentsmemberus gaap foreignplanmemberus gaap insurancecontractsmemberus gaap foreignplanmemberus gaap insurancecontractsmemberus gaap gaap foreignplanmemberus gaap insurancecontractsmemberus gaap gaap foreignplanmemberus gaap gaap insurancecontractsmemberus gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharemembertmo insurancecontractsmemberus gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap gaap gaap foreignplanmemberus gaap gaap gaap foreignplanmemberus gaap gaap gaap foreignplanmemberus gaap gaap fairvaluemeasuredatnetassetvaluepersharememberus gaap foreignplanmemberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap seniornotesmembertmo gaap gaap gaap commercialpapermembertmo gaap commercialpapermembertmo gaap gaap gaap gaap analyticalinstrumentsmemberus gaap inventoriesmemberus gaap gaap gaap financialguaranteemembertmo minimummembertmo maximummembertmo gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap fairvaluehedgingmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap fairvaluehedgingmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap otherexpensememberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap otherexpensememberus gaap foreigncurrencydenominateddebtmemberus gaap designatedashedginginstrumentmemberus gaap foreigncurrencydenominateddebtmemberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap crosscurrencyinterestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap costofsalesmemberus gaap foreignexchangecontractmemberus gaap gaap costofsalesmemberus gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap otherexpensememberus gaap gaap foreignexchangecontractmemberus gaap otherexpensememberus gaap gaap designatedashedginginstrumentmemberus gaap interestrateswapmemberus gaap gaap interestrateswapmemberus gaap otherexpensememberus gaap gaap gaap gaap gaap gaap united state security exchange commissionwashington annual report pursuant section or the security exchange act of the fiscal year ended december or transition report pursuant to section or of the security exchange act of file number fisher scientific inc exact name of registrant specified in it charter state of incorporation employer identification third avenuewaltham massachusetts address of principal executive office zip code registrant telephone number including area code registered pursuant to section of the act title of classtrading symbol name of each exchange registeredcommon stock par valuetmonew york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock note due york stock exchangesecurities registered pursuant to section of the act noneindicate check mark the registrant well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or of the act yes no indicate by check mark whether the registrant filed report required to filed by section or of the security exchange act of the preceding month and ha been subject to filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation during the preceding month yes no indicate by check mark whether the registrant is large accelerated filer accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control financial reporting section of the sarbanes oxley act by the registered public accounting firm prepared or issued it audit report if security registered pursuant to section of the act indicate by check mark whether the financial statement of the registrant included in the filing reflect the correction of an error to previously issued financial statement indicate by check mark whether of error correction are restatement that required recovery analysis of incentive based compensation received by any of the registrant executive officer during the relevant recovery period pursuant to indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no of july the aggregate market value of the voting stock held by nonaffiliates of the registrant approximately based on the last reported sale of common stock on the new york stock exchange composite tape reporting system on july of february the registrant share of common stock outstanding document incorporated by referencesections of thermo fisher definitive proxy statement for the annual meeting of shareholder are incorporated by reference part ii and iii of report thermo fisher scientific inc annual report on form kfor the fiscal year ended december table of contentspagepart iitem risk unresolved staff legal mine safety iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity management discussion and analysis of financial condition and result of quantitative and qualitative disclosure market financial statement and supplementary change in and disagreement accountant on accounting and financial control and disclosure regarding foreign jurisdiction that prevent iiiitem director executive officer and corporate executive security ownership of certain beneficial owner and management and related stockholder certain relationship and related transaction and director principal accountant fee and ivitem exhibit and financial statement form fisher scientific inc part iforward looking statementsforward looking statement within the meaning of section of the security exchange act of the exchange act are made throughout this annual report on form any statement contained herein that are not statement of historical fact may be deemed to be forward looking statement including without limitation statement regarding projection of revenue expense earnings margin tax rate tax provision cash flow pension and benefit obligation and funding requirement and liquidity position cost reduction restructuring activity new product and service development competitive strength or market position acquisition or divestiture growth decline and other trend in market sell into new or modified law regulation and accounting pronouncement outstanding claim legal proceeding tax audit and assessment and other contingent liability foreign currency exchange rate and fluctuation in those rate general economic and capital market condition the timing of any of the foregoing assumption underlying any of the foregoing the expected impact of the covid pandemic on the company business and any other statement that address event or development that thermo fisher intends or belief or may occur in the future without limiting the foregoing the word belief anticipates plan expects seek estimate and similar expression are intended to identify forward looking statement although not all forward looking statement are accompanied by such word the company may elect to update forward looking statement in the future specifically disclaims any obligation to even if the company estimate change and reader not rely on those forward looking statement representing the company view of any date subsequent to the date of the filing of this report number of important factor could cause the result of the company to differ materially those indicated by such forward looking statement including those detailed under the heading risk factor in part item item businessdescription of businessthermo fisher scientific inc also referred to in this document thermo fisher we the company or the registrant is the world leader in serving science our mission is to enable our customer to make the world healthier cleaner and safer we serve customer working in pharmaceutical and biotech company hospital and clinical diagnostic lab university research institution and government agency well environmental industrial research and development quality and process control setting our global team delivers an unrivaled combination of innovative technology purchasing convenience and pharmaceutical service our industry leading brand including thermo scientific applied biosystems invitrogen fisher scientific unity lab service patheon and ppd we continuously increase our depth of capability across our broad portfolio of innovative product and service and leverage our extensive global channel to address our customer need we do this through organic investment in research and development capacity and through acquisition our goal is to enable our customer to be productive in an increasingly competitive business environment and enabling to advance important work business segment and productswe report our business in four segment life science solution analytical instrument specialty diagnostics and laboratory product and biopharma service life science solution segmentthrough our life science solution segment we provide an extensive portfolio of reagent instrument and consumables used in biological and medical research discovery and production of new drug and vaccine well diagnosis of infection and disease product and service are used by customer in pharmaceutical biotechnology agricultural clinical healthcare academic and government market life science solution includes four primary business bioscience genetic science clinical next generation sequencing and bioproduction our bioscience business includes reagent instrument and consumables that help our customer conduct biological and medical research in area such molecular biology and protein biology discover new drug and vaccine and diagnose infection and disease our genetic science business combine wide variety of instrument and related reagent used to provide high value genomic solution to assist customer decision in the research clinical healthcare and applied market our clinical next generation sequencing ng business focus on delivering simple fast and cost effective ng technology for range of application with particular focus on oncology our bioproduction business support developer and manufacturer of biological based therapeutic and vaccine with portfolio of premium solution and service focused on upstream cell fisher scientific inc culture downstream purification analytics for detection and quantitation of process product impurity and suite of single use solution spanning the biologics workflow analytical instrument segmentthrough our analytical instrument segment we provide broad offering of instrument and the supporting consumables software and service that are used for range of application these product and service are used by customer in pharmaceutical biotechnology academic government environmental and other research and industrial market well the clinical laboratory this segment includes three primary business chromatography and mass spectrometry chemical analysis and electron microscopy our chromatography and mass spectrometry business develops and provides analytical instrumentation for organic and inorganic sample analysis across applied technology and scientific research our chemical analysis product fall into three main category production process and analytics field and safety instrument and environmental and process instrument our electron microscopy business serf customer in the life science material science and semiconductor market providing integrated workflow that power research development and production solution specialty diagnostics segmentour specialty diagnostics segment offer wide range of diagnostic test kit reagent culture medium instrument and associated product to serve customer in healthcare clinical pharmaceutical industrial and food safety laboratory our healthcare product are used to increase the speed and accuracy of diagnosis which improves patient care in more cost efficient manner this segment ha five primary business clinical diagnostics immunodiagnostics microbiology transplant diagnostics and our healthcare market channel our clinical diagnostics product include broad offering of liquid ready to use and lyophilized immunodiagnostic reagent kit calibrators control and calibration verification fluid such product are used for among other thing drug of abuse testing therapeutic drug monitoring thyroid hormone testing serum toxicity first trimester screening and tumor marker testing our immunodiagnostics offering include developing manufacturing and marketing complete blood test system to support the clinical diagnosis and monitoring of allergy asthma and autoimmune disease our microbiology offering include dehydrated and prepared culture medium collection and transport system instrumentation and consumables to detect pathogen in blood diagnostic and rapid direct specimen test quality control product and associated product for the microbiology laboratory our transplant diagnostics product include human leukocyte antigen hla typing and testing for the organ transplant market our healthcare market channel offering include broad array of consumables diagnostic kit and reagent equipment instrument solution and service for hospital clinical laboratory reference laboratory physician office and other clinical testing facility laboratory product and biopharma service segmentour laboratory product and biopharma service segment offer virtually everything needed for the laboratory our unique combination of self manufactured and sourced product and extensive service offering enables our customer to focus on their core activity and help them to be more efficient productive and cost effective the segment also includes comprehensive offering of outsourced service used by the pharmaceutical and biotech industry for drug development clinical research clinical trial service and commercial drug manufacturing we serve the pharmaceutical biotechnology academic medical device government and other research and industrial market well the clinical laboratory market through five key business laboratory product laboratory chemical research and safety market channel pharma service and clinical research our laboratory product are used for life science research and drug discovery and development to advance the prevention and cure of disease and enhance quality of life our laboratory chemical offering comprises broad range of chemical solvent and reagent supporting virtually every laboratory application from research and drug discovery to development and manufacturing our research and safety market channel offer mix of product that are manufactured by thermo fisher by third party for on private label basis and by third party under their brand offered for sale through our pharma service business provides the entire spectrum of development manufacturing and clinical trial service for both small molecule and large molecule pharmaceutical our clinical research business offer comprehensive integrated clinical development and analytical service including all phase of development phase iv peri and post approval and site and patient access service during the life science solution and specialty diagnostics segment well the laboratory product business continued to support covid diagnostic testing scaling and evolving their molecular diagnostics solution and plastic consumables business to respond to the on going covid pandemic the bioscience bioproduction and laboratory equipment and consumables business also leveraged their capacity to meet the need of pharma and biotech customer fisher scientific inc rapidly expanded their production volume to meet global vaccine manufacturing requirement additionally through our pharma service business we provided our pharma and biotech customer with the service they needed to develop and produce vaccine and therapy globally sale and marketingwe market and sell our product and service through direct sale force customer service professional electronic commerce and third party distributor our global team delivers combination of innovative technology purchasing convenience and pharmaceutical service through our industry leading brand including thermo scientific applied biosystems invitrogen fisher scientific unity lab service patheon and ppd we have approximately sale personnel including highly trained technical specialist enable to better meet the need of our more technical end user we also provide customer with product standardization and other supply chain management service to reduce procurement cost new product and research and developmentour business includes the development and introduction of new product and may include entry into new business segment we anticipate that we will continue to make significant expenditure for research and development we seek to provide continuing flow of innovative product to maintain and improve our competitive position resourcesraw materialsour management team belief that we have readily available supply of raw material for all of our significant product from various source no single supplier is material although for reason of quality assurance regulatory requirement cost effectiveness availability or uniqueness of design certain material component may be sourced from single supplier or limited number of supplier that readily provide such material or component raw material and fuel price are subject to fluctuation due to market condition we employ many strategy including the use of alternative material to mitigate the effect of these fluctuation on our result patent license and trademarkspatents are important in many aspect of our business no particular patent or related group of patent is so important however that it loss would significantly affect our operation whole appropriate we seek patent protection for invention and development made by our personnel that are incorporated into our product or otherwise fall within our field of interest patent right resulting from work sponsored by outside party do not always accrue exclusively to the company and may be limited by agreement or contract we protect of our technology trade secret and where appropriate we use trademark or register trademark used in connection with product we also enter into license agreement with others to grant and or receive right to intellectual property right all trademark trade name product name graphic and logo of thermo fisher contained herein are trademark or registered trademark of thermo fisher or it subsidiary applicable in the united state and or other country solely for convenience we may refer to trademark in this annual report on form without the and symbol such reference are not intended to indicate in any way that we will not assert to the fullest extent permitted by law our right to our trademark to the extent other trademark appear in this annual report on form they are the property of their respective owner seasonal influencesrevenues in the fourth quarter are historically stronger in other quarter due to the capital spending pattern of industrial pharmaceutical and government customer sale of seasonal product such covid allergy and flu test and related diagnostic product vary quarter to quarter and year to year competitionthe company encounter aggressive and able competition in virtually all of the market we serve of the diversity of our product and service we face many different type of competitor and competition our competitor include broad range of manufacturer third party distributor and service provider competitive climate in many of the market we serve are characterized by changing technology and customer demand that require continuing research and development our success primarily depends on the following factor fisher scientific inc technical performance and advance in technology that result in new product and improved price performance ratio product differentiation availability and reliability the depth of our capability our reputation among customer quality provider of product and service customer service and support active research and application development program and relative price of our product and service government regulationenvironmental regulationswe are subject to various law and governmental regulation concerning environmental matter and employee safety and health in the united state and other country federal environmental legislation that affect includes the toxic substance control act the resource conservation and recovery act the clean air act the clean water act the safe drinking water act and the comprehensive environmental response compensation and liability act cercla we are also subject to regulation by the occupational safety and health administration osha concerning employee safety and health matter the united state environmental protection agency usepa osha and other federal agency have the authority to promulgate regulation that have an effect on our operation in addition to these federal law and regulation various state have been delegated certain authority under the aforementioned federal statute and have authority over these matter under state law many state and local government have adopted environmental and employee safety and health law and regulation some of which are similar to federal requirement number of our operation involve the handling manufacturing use or sale of substance that are or could be classified toxic or hazardous material within the meaning of applicable law consequently some risk of environmental harm is inherent in our operation and product it is with other company engaged in similar business our expense for environmental requirement are incurred generally for ongoing compliance and historical remediation matter based on current information we believe that these compliance cost are not material for historical remediation obligation our expenditure relate primarily to the cost of permitting installing and operating and maintaining groundwater treatment system and other remedial measure our fair lawn and somerville new jersey facility entered into administrative consent order with the new jersey department of environmental protection in to maintain groundwater remediation activity at these site and are currently under the state licensed site remediation professional program the owner of the fair lawn facility we are listed potentially responsible party for remediation within an area called the fair lawn wellfields superfund site and in the company and certain other party entered into consent order with the usepa to complete remedial investigation feasibility study in the usepa issued record of decision setting forth the scope of required remediation work at the site which includes upgrading water treatment plant to address constituent such chlorinated organic compound dioxane and perfluorooctanoic acid perfluorooctane sulfonate pfoa pfos in the court approved consent decree that requires the company and another responsible party to finance and perform the required remediation work with usepa oversight which ha been ongoing and is pending usepa approval of the water treatment plant design in our life technology subsidiary entered into consent decree with the usepa and other responsible party to implement groundwater remedy at the former davis landfill superfund site in smithfield rhode island year of additional study in september usepa revised it cleanup plan by selecting an interim remedial approach that includes groundwater treatment followed by additional monitoring of site condition depending on the result of these treatment and monitoring activity over the next several year usepa anticipates selecting final groundwater remedy for the site in november the consent decree wa amended to reflect the party obligation to implement usepa interim remedy for which pre design work commenced during we record accrual for environmental liability based on current interpretation of environmental law and regulation it is probable that liability ha been incurred and the amount of such liability can be reasonably estimated we calculate estimate based upon several factor including report prepared by environmental specialist and management knowledge and experience with these environmental matter we include in these estimate potential cost for investigation remediation and operation and maintenance of cleanup site accrued liability for environmental matter totaled million at december these environmental liability do not include third party recovery to which we may be entitled we believe that our accrual is adequate for the environmental liability we currently expect to incur result we believe that our ultimate fisher scientific inc liability with respect to environmental matter will not have material adverse effect on our financial position result of operation or cash flow however we may be subject to remedial or compliance cost due to future event such change in existing law and regulation change in agency direction or enforcement policy development in remediation technology change in the conduct of our operation and the effect of change in accounting rule which could have material adverse effect on our financial position result of operation or cash flow for discussion of the environmental law and regulation that the company operation product and service are subject to and other environmental contingency refer to note to our consolidated financial statement other law and regulationsour operation and some of the product and service we offer are subject to number of complex and stringent law and regulation governing the development testing approval production handling transportation and distribution of chemical drug and other similar product including the operating and security standard of the food and drug administration the drug enforcement administration the bureau of alcohol tobacco firearm and explosive and various state board of pharmacy well comparable state and foreign agency thermo fisher business also include export and import activity we are subject to pertinent law enforced by the department of commerce state and treasury in addition our logistics activity must comply with the rule and regulation of the department of transportation the federal aviation administration and similar foreign agency while we believe we are in compliance in all material respect with such law and regulation any noncompliance could result in substantial fine or otherwise restrict our ability to provide competitive distribution service and thereby have an adverse effect on our financial condition to date no such law or regulation have had material impact on our operation we are subject to law and regulation governing government contract and failure to address these law and regulation or comply with government contract could harm our business by leading to reduction in revenue associated with these customer we have agreement relating to the sale of our product to government entity and result we are subject to various statute and regulation that apply to company business with the government we are also subject to investigation for compliance with the regulation governing government contract failure to comply with these regulation could also result in suspension of these contract criminal civil and administrative penalty or debarment for discussion of risk related to change in governmental regulation refer to risk factor in part item human capitalthe success of thermo fisher is fueled by colleague who are highly engaged and feel empowered to achieve their goal everything we do start with our mission to enable our customer to make the world healthier cleaner and safer our colleague understand the role they play in fulfilling that mission and that inspires them to bring their best to work each day our mission is not differentiator for externally but motivator for internally our culture is rooted in our value of integrity intensity innovation and involvement within this framework we strive to create safe fair and positive working environment for our colleague around the world we want our team to feel they have stake in our success voice in our direction and to be empowered to make difference for the key stakeholder we serve every year we conduct an employee involvement survey to solicit direct feedback from our colleague on we doing well and where we need to improve we compile the feedback to measure our progress using three key index leadership involvement and inclusion our continued focus on enhancing our culture help position our company to be an even better place to work we are committed to maintaining the strongest team in our industry focusing on developing and retaining our colleague while leveraging our leadership to attract new colleague to our company of december we employed approximately colleague globally with an approximate regional distribution follows based in the america in the asia pacific region and nearly in europe the middle east and africa emea diversity and inclusionwe recognize that the future aspiration outlined in our vision for which serf our long term roadmap will only be achievable if we have culture that value diversity and inclusion while diversity of gender and ethnicity are important and we re focused on continuously improving for diversity of background experience and viewpoint is equally vital to our long term success when those difference are welcomed and supported we create an inclusive workplace that unlocks the true benefit of diversity diversity and inclusion is not an initiative at thermo fisher it woven into the fabric of our culture and our colleague are encouraged to openly share the wide range of perspective they represent we work together to create an fisher scientific inc inclusive culture where our colleague feel they belong and are empowered to contribute collaborate and innovate embracing individual difference is critical to our success for example thermo fisher wa named top female friendly company best employer for woman and best employer for veteran by forbes in best place to work for disability inclusion well best place to work for lgbtq equality for the seventh consecutive year establishing this kind of environment is critical in empowering our colleague so they can contribute their best idea and bring their true self to work each day our focus is embedded in every stage of our colleague lifecycle from recruiting to onboarding training development and longer term career planning we track our progress on our strategic objective through core set of metric that are reviewed during routine business operating mechanism including quarterly business review human resource review board review and through team dashboard that are shared each month with leader across the company this enables frequent meaningful data driven discussion across our business and function on range of factor including gender and ethnic representation this approach also ensures we consistently prioritize our opportunity to improve we understand the critical role diversity play in sustained business success and our team are empowered to ensure our workforce represents the customer we serve to provide additional transparency to our workforce demographic following our report submission to the equal employment opportunity commission we disclose our eeo report on our website each year we are committed to ensuring our colleague have access to resource awareness training and internal network that offer support and guidance our strategy is greatly enabled by our business resource group brgs which bring together individual with similar interest to share experience learn from each other and collaborate to identify solution to business challenge our brgs reinforce that all colleague can make difference for our customer for each other and for our company of december we had global brgs with more than local brg chapter talent development our overarching goal from talent perspective is to create opportunity for our colleague to achieve their full potential and career aspiration at thermo fisher we focus on the entire lifecycle of colleague career from their initial recruitment to onboarding through ongoing development and training to enhance their skill so they are in the best position to deliver on their goal and achieve their career aspiration in today environment we know talent is key competitive advantage and that building the strongest team in the industry is critical to our future from our colleague referral program summer internship university relation to our graduate leadership development program we continue to build strong internal and external sourcing channel on board talent development at thermo fisher is key organizational capability we continue to make significant investment to support our colleague along every step of their career journey to help support their success our talent development framework incorporates multi faceted approach including formal and self paced training networking opportunity on the job stretch learning coaching mentoring and manager training utilizing contemporary technology solution to support the broad need of our workforce we provide multiple program at all career level from online learning for all colleague through thermo fisher university to focused training for manager at various experience level to our global leadership program for executive we also support our colleague career advancement through our tuition reimbursement program in company our size we can also actively manage our talent through rotational opportunity across our business function and geography that help our colleague gain new experience share knowledge and broaden their skill our executive and leader participate in frequent talent discussion well formal review leveraging workforce data and predictive analytics to better anticipate the talent requirement of our business based on our growth opportunity and market demand thermo fisher is dedicated to talent development to meet our evolving business need and to provide our colleague with opportunity for long and fulfilling career our colleague are passionate about our company and their role in our success and it our responsibility to help them reach their full potential total reward we offer comprehensive total reward package that we regularly evaluate and measure established benchmark to ensure it effectiveness in recruiting and retention and to position thermo fisher an employer of choice in we reinvested approximately million of additional compensation payment to our colleague to help them with the temporary impact of high inflation our health and wellness program provide competitive flexible program that our global colleague and their family can count on for example for colleague we offer choice of comprehensive national medical dental and vision plan fisher scientific inc wellness program including valuable health incentive opportunity and tax advantaged saving and spending account well commuter benefit employee assistance program optional group legal coverage and company paid disability accident and life insurance we also offer company paid proprietary program for cancer care called the impact program which give our colleague and their family access to personalized support and direct line of communication to expert in cancer genetics and genomics similar benefit are available in all country around the world where we operate we also invest in our colleague financial health helping them to grow and protect their saving plan for the future and share in the success of the company they are helping to build we deliver comprehensive reward including competitive base pay and also provide variety of incentive and equity program that by design directly link the impact of colleague contribution to the company overall success disclosure pursuant to section of the exchange actthe russian federal security service the fsb is designated blocked party under executive order while we have paused sale and manufacturing operation in russia and belarus in the normal course of business authorized by general license issued by the department of the treasury office of foreign asset control our russian affiliate responds to regulatory inquiry from the fsb and otherwise engages with the fsb licensing authority these interaction not result in any revenue or otherwise contribute to our net income for the quarter our russian affiliate may respond to similar regulatory inquiry and otherwise continue to engage with the fsb licensing authority in the future necessary and to the extent permitted by applicable sanction law and regulation available informationthe company file annual quarterly and current report proxy statement and other document with the security and exchange commission sec under the exchange act the sec maintains website that contains report proxy and information statement and other information that issuer including the company file electronically with the sec the public can obtain any document that we file with the sec at www sec gov we also make available free of charge on or through our own website at www thermofisher com our annual report on form quarterly report on form current report on form and if applicable amendment to those report filed or furnished pursuant to section of the exchange act soon reasonably practicable after we electronically file such material with or furnish it to the sec in addition paper copy of these document may be obtained free of charge by writing to the company care of it investor relation department at our principal executive office located at third avenue waltham massachusetts information about our executive officersas of february our executive officer nameagepresent title fiscal year first became executive officer other position heldmarc president and chief executive officer president and chief executive officer chief operating officer executive vice president michel vice president and chief operating officer executive vice president senior vice president and president pharma service president and chief operating officer patheon managing director jll partner gianluca vice president senior vice president and president specialty diagnostics president bioscience president china michael vice president and general counsel senior vice president general counsel and secretary executive vice president and group general counsel luxottica group stephen vice president and chief financial officer vice president financial operation joseph president and chief accounting officer senior director technical accounting fisher scientific inc item risk factorsset forth are the risk that we believe are material to our investor this section contains forward looking statement should refer to the explanation of the qualification and limitation on forward looking statement in item business under the caption forward looking statement industry and economic risksour growth would suffer if the market into which we sell our product and service decline do not grow anticipated or experience cyclicality our growth depends in part on the growth of the market which we serve any decline or lower than expected growth in our served market would diminish demand for our product and service which would adversely affect our financial statement certain of our business operate in industry that may experience periodic cyclical downturn our business is affected by general economic condition and related uncertainty affecting market in which we operate our business is affected by general economic condition both inside and outside the both domestic and international market experienced significant inflationary pressure in and inflation rate in the well in other country in which we operate continue at elevated level for the near term if the global economy and financial market or economic condition in europe the or other key market continue to be unstable they could adversely affect the business result of operation and financial condition of the company and it customer distributor and supplier the effect of reducing demand for some of our product increasing the rate of order cancellation or delay increasing the risk of excess and obsolete inventory increasing pressure on the price for our product and service causing supply interruption which could disrupt our ability to produce our product and creating longer sale cycle and greater difficulty in collecting sale proceeds and slower adoption of new technology economic political foreign currency and other risk associated with international sale and operation could adversely affect our result of operation international market contribute substantial portion of our revenue and we intend to continue expanding our presence in these region the exposure to fluctuation in currency exchange rate take on different form international revenue and cost are subject to the risk that fluctuation in exchange rate could adversely affect our reported revenue and profitability when translated into dollar for financial reporting purpose these fluctuation could also adversely affect the demand for product and service provided by multinational corporation our business occasionally invoice third party customer in currency other than the one in which they primarily do business which we refer to the functional currency movement in the invoiced currency relative to the functional currency could adversely impact our cash flow and our result of operation our international sale grow exposure to fluctuation in currency exchange rate could have larger effect on our financial result in currency translation had an unfavorable effect of billion on revenue due to the strengthening of the dollar relative to other currency in which the company sell product and service some emerging market country may be particularly vulnerable to period of global and local political legal regulatory and financial instability including issue of geopolitical relation the imposition of international sanction in response to certain state action and or sovereign debt issue and may have higher incidence of corruption and fraudulent business practice result of these and other factor our strategy to grow in emerging market may not be successful and growth rate in these market may not be sustainable in addition many of our employee contract manufacturer supplier job function outsourcing activity and manufacturing facility are located outside the accordingly our future result could be harmed by variety of factor including interruption to transportation flow for delivery of part to and finished good to our customer change in specific country or region political economic or other condition change in diplomatic and trade relationship including new tariff trade protection measure import or export licensing requirement trade embargo and sanction and other trade barrier fisher scientific inc tariff imposed by the on good from other country and tariff imposed by other country on good including the tariff adopted by the government on various import from china and by the chinese government on certain good the impact of public health epidemic pandemic on the global economy such the covid pandemic uncertainty regarding the collectability of account receivable the imposition of governmental control diverse data privacy and protection requirement supply interruption which could disrupt our ability to produce our product increase in material energy labor or other manufacturing related cost or higher supply chain logistics cost negative consequence from change in tax law difficulty in staffing and managing widespread operation differing labor regulation differing protection of intellectual property unexpected change in regulatory requirement and geopolitical uncertainty or turmoil including terrorism and war demand for some of our product depends on capital spending policy of our customer and on government funding policy our customer include pharmaceutical and chemical company laboratory university healthcare provider government agency and public and private research institution many factor including public policy spending priority available resource and product and economic cycle have significant effect on the capital spending policy of these entity spending by some of these customer fluctuates based on budget allocation and the timely passage of the annual federal budget an impasse in federal government budget decision could lead to substantial delay or reduction in federal spending we are subject to risk associated with public health epidemic and pandemic such the ongoing covid pandemic our global operation expose to risk associated with public health epidemic and pandemic covid ha had an adverse impact on certain of our operation supply chain and distribution system and we may experience unpredictable reduction in supply and demand for certain of our product and service national state and local government have implemented and may continue to implement safety precaution including quarantine border closure increased border control travel restriction shelter in place order and shutdown and other measure these measure may disrupt normal business operation and may have significant negative impact on business and financial market worldwide our ability to continue to manufacture product is highly dependent on our ability to maintain the safety and health of our factory employee the ability of our employee to work may be significantly impacted by the covid pandemic or future epidemic and pandemic in addition the duration and extent of future revenue from sale of product related to the covid response are uncertain and dependent primarily on customer testing demand well therapy and vaccine demand business riskswe must develop new product adapt to rapid and significant technological change respond to introduction of new product by competitor and maintain quality to remain competitive our growth strategy includes significant investment in and expenditure for product development we sell our product in several industry that are characterized by rapid and significant technological change frequent new product and service introduction and enhancement and evolving industry standard competitive factor include technological innovation price service and delivery breadth of product line customer support business capability and the ability to meet the special requirement of customer our competitor may adapt more quickly to new technology and change in customer requirement than we can without the timely introduction of new product service and enhancement our product and service will likely become technologically obsolete over time in which case our revenue and operating result would suffer many of our existing product and those under development are technologically innovative and require significant planning design development and testing at the technological safety quality product and manufacturing process level our customer use many of our product to develop test and manufacture their own product result we must anticipate industry trend and develop product in advance of the commercialization of our customer product if we fail to adequately develop product or predict our customer need and future activity we may invest heavily in research and development of product and service that do not lead to significant revenue fisher scientific inc it may be difficult for to implement our strategy for improving internal growth our growth depends in part on the growth of the market which we serve any decline or lower than expected growth in our served market could diminish demand for our product and service which would adversely affect our result of operation and financial condition to address this issue we are pursuing number of strategy to improve our internal growth including strengthening our presence in selected geographic market allocating research and development funding to product with higher growth prospect developing new application for our technology expanding our service offering continuing key customer initiative combining sale and marketing operation in appropriate market to compete more effectively finding new market for our product and continuing the development of commercial tool and infrastructure to increase and support cross selling opportunity of product and service to take advantage of our depth in product offering we may not be able to successfully implement these strategy and these strategy may not result in the expected growth of our business because we compete directly with certain of our larger customer and product supplier our result of operation could be adversely affected in the short term if these customer or supplier abruptly discontinue or significantly modify their relationship with our largest customer in the laboratory product business is also significant competitor our business may be harmed in the short term if our competitive relationship in the marketplace with certain of our large customer result in discontinuation of their purchase from in addition we manufacture product that compete directly with product that we source from third party supplier we also source competitive product from multiple supplier our business could be adversely affected in the short term if any of our large third party supplier abruptly discontinues selling product to our inability to complete any pending acquisition or to successfully integrate any new or previous acquisition could have material adverse effect on our business our business strategy includes the acquisition of technology and business that complement or augment our existing product and service certain acquisition may be difficult to complete for number of reason including the need for antitrust and or other regulatory approval well dispute or litigation any acquisition we may complete may be made at substantial premium over the fair value of the net identifiable asset of the acquired company further we may not be able to integrate acquired business successfully into our existing business make such business profitable or realize anticipated cost saving or synergy if any from these acquisition which could adversely affect our business moreover we have acquired many company and business result of these acquisition we recorded significant goodwill and indefinite lived intangible asset primarily tradenames on our balance sheet which amount to approximately billion and billion respectively of december in addition we have definite lived intangible asset totaling billion of december we ass the realizability of goodwill and indefinite lived intangible asset annually well whenever event or change in circumstance indicate that these asset may be impaired we ass the realizability of definite lived intangible asset whenever event or change in circumstance indicate that these asset may be impaired these event or circumstance would generally include operating loss or significant decline in earnings associated with the acquired business or asset our ability to realize the value of the goodwill and intangible asset will depend on the future cash flow of these business these cash flow in turn depend in part on well we have integrated these business if we are not able to realize the value of the goodwill and intangible asset we may be required to incur material charge relating to the impairment of those asset operational risksour reliance upon sole or limited source of supply for certain material or component could cause production interruption delay and inefficiency some of our business purchase certain material from sole or limited source supplier for reason of quality assurance regulatory requirement cost effectiveness availability or uniqueness of design if these or other supplier encounter financial operating or other difficulty or if our relationship with them change we might not be able to quickly establish or qualify replacement source of supply the supply chain for our business could also be disrupted by supplier capacity constraint bankruptcy or exiting of the business for other reason decreased availability or increased cost of key raw material or commodity such energy and external event such global economic downturn and macroeconomic trend natural disaster pandemic health issue such covid war terrorist action governmental fisher scientific inc action and legislative or regulatory change any of these factor could result in production interruption delay extended lead time and inefficiency significant disruption in or breach in security of our information technology system or violation of data privacy law could adversely affect our business part of our ongoing effort to upgrade our current information system we periodically implement new enterprise resource planning software and other software application to manage certain of our business operation we implement and add functionality problem could arise that we have not foreseen such problem could disrupt our ability to provide quote take customer order and otherwise run our business in timely manner when we upgrade or change system we may suffer interruption in service loss of data or reduced functionality in addition if our new system fail to provide accurate pricing and cost data our result of operation and cash flow could be adversely affected we also rely on our information technology system to process transmit and store electronic information including sensitive data such confidential business information and personally identifiable data relating to employee customer and other business partner and to manage or support variety of critical business process and activity such interacting with supplier selling our product and service fulfilling order and billing collecting and making payment shipping product providing service and support to customer tracking customer activity fulfilling contractual obligation and otherwise conducting business our system may be vulnerable to damage or interruption from natural disaster power loss telecommunication failure terrorist attack computer hacker computer virus ransomware phishing computer denial of service attack unauthorized access to customer or employee data or company trade secret and other attempt to harm our system certain of our system are not redundant and our disaster recovery planning is not sufficient for every eventuality despite any precaution we may take such problem could result in among other consequence interruption in our service which could harm our reputation and financial result our key business partner face similar risk and any security breach of their system could adversely affect our security posture any of the cyber attack breach or other disruption or damage described if significant could materially interrupt our operation delay production and shipment result in theft of our and our customer intellectual property and trade secret damage customer business partner and employee relationship and our reputation or result in defective product or service legal claim and proceeding liability and penalty under privacy law and increased cost for security and remediation each of which could adversely affect our business and financial result our liability insurance may not be sufficient in type or amount to cover against claim related to security breach cyber attack and other related breach if we are unable to maintain reliable information technology system and appropriate control with respect to global data privacy and security requirement and prevent data breach we may suffer regulatory consequence in addition to business consequence global organization we are subject to data privacy and security law regulation and customer imposed control in numerous jurisdiction result of having access to and processing confidential personal and or sensitive data in the course of our business for example in the individual state regulate data breach and security requirement and multiple governmental body assert authority over aspect of the protection of personal privacy european law require to have an approved legal mechanism to transfer personal data of europe and the eu general data protection regulation imposes significantly stricter requirement in how we collect and process personal data several country such china have passed law that require personal data relating to their citizen to be maintained on local server and impose additional data transfer restriction government enforcement action can be costly and interrupt the regular operation of our business and data breach or violation of data privacy law can result in fine reputational damage and civil lawsuit any of which may adversely affect our business reputation and financial statement we may have difficulty attracting and retaining highly qualified workforce our success is largely dependent upon our ability to attract and retain highly qualified scientific technical clinical and management workforce in highly competitive environment qualified individual are in high demand and we may incur significant cost to attract them we may face difficulty in attracting and retaining key talent for number of reason including management change or recruitment by competitor our ability to attract and retain key talent also depends in part on how well we maintain strong workplace culture that is attractive to employee macroeconomic condition specifically increased competition for employee and wage inflation could have material impact on our ability to attract and retain talent our turnover rate and the cost of operating our business we can not ensure that we will be able to hire or retain the personnel necessary for our operation or that the loss of any personnel will not have material impact on our financial condition and result of operation we may incur unexpected cost from increase in fuel and raw material price which could reduce our earnings and cash flow our primary commodity exposure are for fuel petroleum based resin and steel the cost for these commodity well the cost of transportation construction and service necessary for the production and distribution of our product continue to increase and be volatile while we may seek to minimize the impact of price increase through higher price to customer and various cost saving measure our earnings and cash flow could be adversely affected in the event these measure are insufficient to cover our cost fisher scientific inc because we rely heavily on third party package delivery service significant disruption in these service or significant increase in price may disrupt our ability to ship product increase our cost and lower our profitability we ship significant portion of our product to our customer through independent package delivery company such federal express in the and dhl in europe we also maintain small fleet of vehicle dedicated to the delivery of our product and ship our product through other carrier including national and regional trucking firm overnight carrier service and the postal service if one or more of these third party package delivery provider were to experience major work stoppage preventing our product from delivered in timely fashion or causing to incur additional shipping cost we could not pas on to our customer our cost could increase and our relationship with certain of our customer could be adversely affected in addition if one or more of these third party package delivery provider were to increase price and we were not able to find comparable alternative or make adjustment in our delivery network our profitability could be adversely affected natural disaster public health crisis political crisis and other catastrophic event or other event outside of our control may disrupt our facility or the facility of third party on which we depend and could impact customer spending we have significant operation in california near major earthquake fault which make susceptible to earthquake risk an earthquake or other natural disaster including the effect of climate change such sea level rise drought flooding wildfire and more intense weather event could disrupt our operation or impair our critical system any of these disruption or other event outside of our control such strike or other labor unrest could have an adverse effect on our result of operation in addition if any of our facility including our manufacturing or warehouse facility or the facility of our supplier third party service provider or customer is affected by natural disaster such earthquake tsunami power shortage or outage fire flood or monsoon public health crisis such pandemic and epidemic political crisis such terrorism war political instability or other conflict or other event outside of our control such trade protectionism strike or other labor unrest our result of operation could be adversely affected moreover these type of event could negatively impact customer spending in the impacted region or depending upon the severity globally which could also adversely impact our operating result increasing attention to environmental social and governance matter may impact our business financial result stock price or reputation we face increasing scrutiny from stakeholder related to our environmental social and governance esg practice and disclosure including practice and disclosure related to climate change diversity and inclusion and governance standard investor advocacy group certain institutional investor lender investment fund and other influential investor are also increasingly focused on esg practice and disclosure and in recent year have placed increasing importance on the implication and social cost of their investment in addition government organization are enhancing or advancing legal and regulatory requirement specific to esg matter the heightened stakeholder focus on esg issue related to our business requires the continuous monitoring of various and evolving law regulation standard and expectation and the associated reporting requirement failure to adequately meet evolving stakeholder expectation may result in noncompliance the loss of business reputational impact diluted market valuation an inability to attract customer and an inability to attract and retain top talent in addition if legislation or regulation are enacted or promulgated in the or in any other jurisdiction in which we do business that impose more stringent restriction and requirement than our current legal or regulatory obligation we and company in our supply chain may experience increased compliance burden and cost to meet the regulatory obligation which could cause disruption in the sourcing manufacturing and distribution of our product and adversely affect our business financial condition or result of operation in addition our adoption of certain standard or mandated compliance to certain requirement could necessitate additional investment that could impact our profitability legal quality and regulatory riskschanges in governmental regulation may reduce demand for our product or increase our expense we compete in many market in which we and our customer must comply with federal state local and international regulation such environmental health and safety and food and drug regulation we develop configure and market our product to meet customer need created by those regulation any significant change in regulation could reduce demand for our product or increase our expense for example we manufacture pharmaceutical and many of our instrument are marketed to the pharmaceutical industry for use in discovering and developing drug change in the food and drug administration the fda regulation of the drug discovery and development process could have an adverse effect on the demand for these product we are subject to law and regulation governing government contract and failure to address these law and regulation or comply with government contract could harm our business by leading to reduction in revenue associated with these customer we have agreement relating to the sale of our product to government entity and result we are subject to various statute and regulation that apply to company doing business with the government the law governing government contract differ from the law governing private contract and government contract may contain pricing term and condition that are not applicable to private contract we are also subject to investigation for compliance with the fisher scientific inc regulation governing government contract failure to comply with these regulation could result in suspension of these contract criminal civil and administrative penalty or debarment our pharma service offering are highly complex and if we are unable to provide quality and timely offering to our customer our business could suffer our pharma service offering are highly exacting and complex due in part to strict quality and regulatory requirement our operating result in this business depend on our ability to execute and when necessary improve our quality management strategy and system and our ability to effectively train and maintain our employee base with respect to quality management failure of our quality control system could result in problem with facility operation or preparation or provision of product in each case such problem could arise for variety of reason including equipment malfunction failure to follow specific protocol and procedure problem with raw material or environmental factor and damage to or loss of manufacturing operation such problem could affect production of particular batch or series of batch of product requiring the destruction of such product or halt of facility production altogether in addition our failure to meet required quality standard may result in our failure to timely deliver product to our customer which in turn could damage our reputation for quality and service any such failure could among other thing lead to increased cost lost revenue reimbursement to customer for lost drug product registered intermediate registered starting material and active pharmaceutical ingredient other customer claim damage to and possibly termination of existing customer relationship time and expense spent investigating the cause and depending on the cause similar loss with respect to other batch or product production problem in our drug and biologic manufacturing operation could be particularly significant because the cost of raw material for such manufacturing is often high if problem in preparation or manufacture of product or failure to meet required quality standard for that product are not discovered such product is released to the market we may be subject to adverse regulatory action including product recall product seizure injunction to halt manufacture and distribution restriction on our operation civil sanction including monetary sanction and criminal action in addition such problem or failure could subject to litigation claim including claim from our customer for reimbursement for the cost of lost or damaged active pharmaceutical ingredient the cost of which could be significant we are subject to product and other liability risk for which we may not have adequate insurance coverage we may be named defendant in product liability or error and omission lawsuit which may allege that product or service we have provided have resulted or could result in an unsafe condition property damage or injury to end user or financial loss for consumer additionally product currently or previously sold by our environmental and process instrument and radiation measurement and security instrument business include fixed and portable instrument used for chemical radiation and trace explosive detection these product are used in airport embassy cargo facility border crossing and other high threat facility for the detection and prevention of terrorist act if any of these product were to malfunction it is possible that explosive or radioactive material could fail to be detected by our product which could lead to product liability claim in addition patient involved in our clinical service trial conducted by our clinical development service business or taking drug approved on the basis of those trial may also bring personal injury claim against are also many other factor beyond our control that could lead to liability claim such the reliability and competence of the customer operator and the training of such operator any such product liability claim brought against could be significant and any adverse determination may result in liability subject to insurance policy exclusion where insurance would not respond or in excess of our insurance coverage although we carry product liability and error and omission insurance we can not be certain that our current insurance will be sufficient to cover these claim or that it can be maintained on acceptable term if at all we are required to comply with wide variety of law and regulation and are subject to regulation by various federal state and foreign agency we are subject to various local state federal foreign and transnational law and regulation which include the operating and security standard of the fda the drug enforcement agency the dea various state board of pharmacy state health department the department of health and human service the dhhs the european medicine agency the ema the eu member state and other comparable agency and in the future any change to such law and regulation could adversely affect in particular we are subject to law and regulation concerning current good manufacturing practice and drug safety our subsidiary may be required to register for permit and or license with and may be required to comply with the law and regulation of the dea the fda the dhhs foreign agency including the ema and other various state board of pharmacy state health department and or comparable state agency well certain accrediting body depending upon the type of operation and location of product distribution manufacturing and sale the manufacture distribution and marketing of many of our product and service including medical device and our pharma and clinical development service are subject to extensive ongoing regulation by the fda the dea the ema and other equivalent local state federal and non regulatory authority in addition we are subject to inspection by these regulatory authority failure by or by our customer to comply with the requirement of these regulatory authority fisher scientific inc including without limitation remediating any inspectional observation to the satisfaction of these regulatory authority could result in warning letter product recall or seizure monetary sanction injunction to halt manufacture and distribution restriction on our operation civil or criminal sanction or withdrawal of existing or denial of pending approval including those relating to product or facility in addition such failure could expose to contractual or product liability claim contractual claim from our customer including claim for reimbursement for lost or damaged active pharmaceutical ingredient or personal injury well ongoing remediation and increased compliance cost any or all of which could be significant we are the sole manufacturer of number of pharmaceutical for many of our customer and negative regulatory event could impact our customer ability to provide product to their customer we are also subject to variety of federal state local and international law and regulation that govern among other thing the handling transportation and manufacture of substance that could be classified hazardous and we are required to comply with various import law and export control and economic sanction law which may affect our transaction with certain customer in certain circumstance export control and economic sanction regulation may prohibit the export of certain product service and technology in other circumstance we may be required to obtain an export license before exporting the controlled item compliance with the various import law that apply to our business can restrict our access to and increase the cost of obtaining certain product and at time can interrupt our supply of imported inventory any noncompliance by with applicable law and regulation or the failure to maintain renew or obtain necessary permit and license could result in criminal civil and administrative penalty and could have an adverse effect on our result of operation our reputation ability to do business and financial statement may be impaired by improper conduct by any of our employee agent business partner or other third party we have internal control and compliance system to protect the company against act committed by employee agent or business that we acquire that would violate and or non law including the law governing payment to government official bribery fraud kickback and false claim pricing sale and marketing practice conflict of interest competition employment practice and workplace behavior export and import compliance money laundering and data privacy but these control and system may not be sufficient to prevent every such wrongful act in particular the foreign corrupt practice act the bribery act and similar anti bribery law in other jurisdiction generally prohibit company and their intermediary from making improper payment to government official for the purpose of obtaining or retaining business and we operate in many part of the world that have experienced governmental corruption to some degree any such improper action or allegation of such act could damage our reputation and subject to civil or criminal investigation in the and in other jurisdiction and related shareholder lawsuit could lead to substantial civil and criminal monetary and nonmonetary penalty and could cause to incur significant legal and investigatory fee in addition the government may seek to hold liable for violation committed by company which we acquire we also rely on our supplier to adhere to our supplier standard of conduct and material violation of such standard of conduct could occur that could have material effect on our business reputation and financial statement in addition any allegation of issue resulting from the misuse of our product could even if untrue adversely affect our reputation and our customer willingness to purchase product from any such allegation could cause to lose customer and divert our resource from other task which could materially and adversely affect our business and operating result our inability to protect our intellectual property could have material adverse effect on our business in addition third party may claim that we infringe their intellectual property and we could suffer significant litigation or licensing expense result we place considerable emphasis on obtaining patent and trade secret protection for significant new technology product and process because of the length of time and expense associated with bringing new product through the development process and into the marketplace our success depends in part on our ability to develop patentable product and obtain and enforce patent protection for our product both in the and in other country we own numerous and foreign patent and we intend to file additional application appropriate for patent covering our product patent may not be issued for any pending or future patent application owned by or licensed to and the claim allowed under any issued patent may not be sufficiently broad to protect our technology any issued patent owned by or licensed to may be challenged invalidated or circumvented and the right under these patent may not provide with competitive advantage in addition competitor may design around our technology or develop competing technology intellectual property right may also be unavailable or limited in some foreign country which could make it easier for competitor to capture increased market position we could incur substantial cost to defend in suit brought against or in suit in which we may assert our patent right against others an unfavorable outcome of any such litigation could materially adversely affect our business and result of operation we also rely on trade secret and proprietary know how with which we seek to protect our product in part by confidentiality agreement with our collaborator employee and consultant these agreement may not adequately protect our trade secret and other proprietary right these agreement may be breached and we may not have adequate remedy for any breach in addition our trade secret may otherwise become known or be independently developed by our competitor fisher scientific inc we also depend in part on our trademark and the strength of our proprietary brand which we consider important to our business if we are unable to protect or preserve the value of our intellectual property right for any reason including our inability to successfully defend against counterfeit knock offs grey market infringing or otherwise unauthorized product our brand and reputation could be damaged and our business may be harmed third party may assert claim against to the effect that we are infringing on their intellectual property right in the event that claim relating to intellectual property is asserted against or third party not affiliated with hold pending or issued patent that relate to our product or technology we may seek license to such intellectual property or challenge those patent however we may be unable to obtain these license on commercially reasonable term if at all and our challenge of the patent may be unsuccessful our failure to obtain the necessary license or other right could prevent the sale manufacture or distribution of our product and therefore could have material adverse effect on our business financial condition and result of operation risk relating to financial profilefluctuations in our effective tax rate may adversely affect our result of operation and cash flow global company we are subject to taxation in numerous country state and other jurisdiction in preparing our financial statement we record the amount of tax that is payable in each of the country state and other jurisdiction in which we operate our future effective tax rate however may be lower or higher than experienced in the past due to numerous factor including change in the mix of our profitability from country to country change in accounting for income tax the result of examination and audit of our tax filing and recently enacted and future change in tax law in jurisdiction in which we operate any of these factor could cause to experience an effective tax rate significantly different from previous period or our current expectation which could have an adverse effect on our business result of operation and cash flow our existing and future indebtedness may restrict our investment opportunity or limit our activity and negatively impact our credit rating of december we had approximately billion in outstanding indebtedness in addition we have availability to borrow under revolving credit facility that provides for to billion of unsecured multi currency revolving credit the facility we may also obtain additional long term debt and line of credit to meet future financing need which would have the effect of increasing our total leverage our leverage could have negative consequence including increasing our vulnerability to adverse economic and industry condition limiting our ability to obtain additional financing and limiting our ability to acquire new product and technology through strategic acquisition our ability to make scheduled payment refinance our obligation or obtain additional financing will depend on our future operating performance and on economic financial competitive and other factor beyond our control our business may not generate sufficient cash flow to meet our obligation if we are unable to service our debt refinance our existing debt or obtain additional financing we may be forced to delay strategic acquisition capital expenditure or research and development expenditure additionally the agreement governing our debt require that we maintain financial ratio and contain affirmative and negative covenant that restrict our activity by among other limitation limiting our ability to incur additional indebtedness merge or consolidate with other entity and create lien the covenant in the facility include consolidated net interest coverage ratio consolidated ebitda to consolidated net interest expense such term are defined in the facility specifically the company ha agreed that so long any lender ha any commitment under the facility any letter of credit is outstanding under the facility or any loan or other obligation is outstanding under the facility it will maintain minimum consolidated net interest coverage ratio of of the last day of any fiscal quarter our ability to comply with these financial restriction and covenant is dependent on our future performance which is subject to prevailing economic condition and other factor including factor that are beyond our control such the impact of foreign exchange rate and interest rate our failure to comply with any of these restriction or covenant may result in an event of default under the applicable debt instrument which could permit acceleration of the debt under that instrument and require to prepay that debt before it scheduled due date also an acceleration of the debt under certain of our debt instrument would trigger an event of default under other of our debt instrument item unresolved staff commentsnone item propertiesthe company owns and lease office engineering laboratory production and warehouse space throughout the world fisher scientific inc item legal proceedingsthere are various lawsuit and claim against the company involving product liability intellectual property employment and commercial issue see note to our consolidated financial statement commitment and contingency item mine safety disclosuresnot applicable part iiitem market for the registrant common equity related stockholder matter and issuer purchase of equity securitiesmarket price of common stockour common stock is traded on the new york stock exchange under the symbol tmo holder of common stockas of february the company had holder of record of it common stock this not include holding in street or nominee name issuer purchase of equity securitiesa summary of the share repurchase activity for the company fourth quarter of follows periodtotal number of share purchasedaverage price paid per sharetotal number of share purchased part of publicly announced plan or program maximum dollar amount of share that may yet be purchased under the plan or program in million fiscal october oct nov fiscal november nov dec fiscal december dec dec total fourth on september the board of director authorized the repurchase of up to billion of the company common stock all of the share of common stock repurchased by the company during the fourth quarter were purchased under this program depleting the authorization on november the board of director authorized the repurchase of up to billion of the company common stock early in the first quarter of the company repurchased billion of the company common stock million share at february billion wa available for future repurchase of the company common stock under this authorization item reservednot applicable item management discussion and analysis of financial condition and result of operationsreference is made throughout this management discussion and analysis of financial condition and result of operation to note to the consolidated financial statement which begin on page of this report management discussion and analysis of financial condition and result of operation for is included in item of the company annual report on form filed with the security and exchange commission the company refers to various amount or measure not prepared in accordance with generally accepted accounting principle non gaap measure these non gaap measure are further described and reconciled to their directly comparable amount or measure under the section non gaap measure later in this management discussion and analysis of financial condition and result of operation overviewthermo fisher scientific inc enables customer to make the world healthier cleaner and safer by helping them accelerate life science research solve complex analytical challenge increase laboratory productivity and improve patient health through fisher scientific inc diagnostics and the development and manufacture of life changing therapy market served include pharmaceutical and biotech academic and government industrial and applied well healthcare and diagnostics the company operation fall into four segment note life science solution analytical instrument specialty diagnostics and laboratory product and biopharma service consolidated result dollar in million except per share amount gaap operating income gaap operating income ptadjusted operating income non gaap measure adjusted operating income margin non gaap measure ptgaap diluted earnings per share attributable to thermo fisher scientific inc adjusted earnings per share non gaap measure organic revenue growthrevenue impact of impact of currency translation organic revenue growth non gaap measure result may not sum due to rounding since the life science solution and specialty diagnostics segment well the laboratory product business have supported covid diagnostic testing scaling and evolving their molecular diagnostics solution and plastic consumables business to respond to the ongoing covid pandemic the bioscience and bioproduction business have expanded their capacity to meet the need of pharma and biotech customer they have expanded their own production volume to meet global vaccine manufacturing requirement additionally our pharma service business ha provided our pharma and biotech customer with the service they needed to develop and produce vaccine and therapy globally while these positive impact are expected to continue through the duration and extent of future revenue from such sale are uncertain and dependent primarily on customer testing well therapy and vaccine demand sale of product related to covid testing were billion and billion in and respectively during demand from pharma and biotech customer wa strong driven by our differentiated customer value proposition and trusted partner status we saw good growth in the academic and government market we remain well positioned to meet customer need the industrial and applied market wa strong driven by robust demand for our analytical instrument serving our semi conductor and material science customer the diagnostics and healthcare market declined due to decreased demand for covid testing product during robust sale growth in north america and the asia pacific region including china wa partially offset by decline in covid testing demand in europe strong sale were more than offset during due to lower covid testing demand contribution to organic revenue during were driven by the laboratory product and biopharma service and analytical instrument segment offset by the life science solution and specialty diagnostics segment the company continues to execute it proven growth strategy which consists of three pillar developing high impact innovative new product leveraging our scale in high growth and emerging market and delivering unique value proposition to our customer gaap operating income margin and adjusted operating income margin decreased in due primarily to lower covid testing volume continued strategic growth investment and the expected impact of incorporating recent acquisition this wa partially offset by strong pricing realization across all segment to address higher inflation while also driving strong productivity gaap operating income margin in wa also impacted by higher amortization expense result of acquisition the company reference to strategic growth investment generally refer to targeted spending for enhancing commercial capability including expansion of geographic sale reach and commerce platform marketing initiative expanded service and operational infrastructure research and development project and other expenditure to enhance the customer experience well incentive compensation and recognition for employee the company reference throughout this discussion to fisher scientific inc productivity improvement generally refer to improved cost efficiency from it practical process improvement ppi business system including reduced cost resulting from implementing continuous improvement methodology global sourcing initiative lower cost structure following restructuring action including headcount reduction and consolidation of facility and low cost region manufacturing notable recent acquisitionson january the company acquired within the laboratory product and biopharma service segment the belgium based european viral vector manufacturing business of groupe novasep sa the european viral vector manufacturing business provides manufacturing service for vaccine and therapy to biotechnology company and large biopharma customer the acquisition expands the segment capability for cell and gene vaccine and therapy on february the company acquired within the life science solution segment mesa biotech inc based molecular diagnostic company mesa biotech ha developed and commercialized pcr based rapid point of care testing platform available for detecting infectious disease including covid the acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care on september the company assumed operating responsibility within the laboratory product and biopharma service segment of new state of the art biologics manufacturing facility in lengnau switzerland from csl limited to perform pharma service for csl with capacity to serve other customer well on december the company acquired within the laboratory product and biopharma service segment ppd inc based global provider of clinical research service to the pharma and biotech industry the addition of ppd clinical research service enhances our offering to biotech and pharma customer by enabling them to accelerate innovation and increase their productivity within the drug development process on december the company acquired within the life science solution segment peprotech inc based developer and manufacturer of recombinant protein peprotech provides bioscience reagent known recombinant protein including cytokine and growth factor the acquisition expands the segment bioscience offering on january the company acquired within the specialty diagnostics segment the binding site group based provider of specialty diagnostic assay and instrument to improve the diagnosis and management of blood cancer and immune system disorder the acquisition expands the segment portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma segment resultsthe company management evaluates segment operating performance using operating income before certain charge credit defined in note accordingly the following segment data are reported on this basis dollar in million science solution analytical specialty laboratory product and biopharma elimination consolidated revenue life science solutionsorganic non gaap measure dollar in million divestituresrevenues segment income segment income ptthe decrease in organic revenue in wa primarily due to lower revenue in the genetic science business driven by moderation in testing demand to diagnose covid partially offset by growth in the bioproduction business the decrease in segment income margin resulted primarily from business mix and strategic growth investment partially offset by productivity improvement fisher scientific inc analytical instrumentsorganic non gaap measure dollar in million divestituresrevenues segment segment income ptthe increase in organic revenue in wa due to increased demand across all the segment business with particular strength in the electron microscopy and chromatography and mass spectrometry business the increase in segment income margin resulted primarily from profit on higher sale productivity improvement and business mix offset in part by strategic growth investment specialty diagnosticsorganic non gaap measure dollar in million divestituresrevenues segment segment income ptthe decrease in organic revenue in wa primarily driven by product addressing diagnosis of covid partially offset by growth in the immunodiagnostics and transplant diagnostics business the decrease in segment income margin wa primarily due to lower covid testing volume largely offset by productivity improvement and positive business mix segment income margin in wa also impacted by million credit to cost of product revenue result of changing the method of accounting for inventory laboratory product and biopharma servicesorganic non gaap measure dollar in million divestituresrevenues segment segment income ptthe increase in organic revenue in wa primarily due to higher sale across each of the segment business with particular strength in the pharma service business and research and safety market channel ppd the company clinical research business contributed billion of revenue during the increase in segment income margin wa primarily due to the benefit of recent acquisition profit on higher sale and productivity improvement offset in part by strategic growth investment segment income margin in wa also impacted by million credit to cost of product revenue result of changing the method of accounting for inventory result may not sum due to roundingnon operating item dollar in million interest expense gaap other income expense adjusted other income expense non gaap measure gaap tax adjusted tax rate non gaap measure net interest expense interest expense le interest income decreased due primarily to lower average interest rate on debt and higher average interest rate on cash balance partially offset by the increase in debt to finance the acquisition of ppd and for general corporate purpose see additional discussion under the caption liquidity and capital resource below gaap other income expense and adjusted other income expense includes currency transaction gain loss on non operating monetary asset and liability and net periodic pension benefit cost income excluding the service cost component gaap other income expense in also includes million of net loss on investment million of loss on the fisher scientific inc early extinguishment of debt note partially offset by million of net gain on derivative instrument to address certain foreign currency risk and million of net settlement gain on pension plan gaap other income expense in also includes million of loss on the early extinguishment of debt and million of financing cost associated with obtaining bridge financing commitment in connection with the agreement to acquire ppd note offset in part by million of net gain on investment the company gaap and adjusted tax rate decreased in compared to primarily due to release of valuation allowance of million in in jurisdiction where the deferred tax asset are expected to be realized the company gaap tax rate wa also impacted by change in tax rate and higher amortization expense result of acquisition well net benefit of million resulting from tax audit settlement see note the company gaap and adjusted tax rate were also impacted by income tax benefit on intra entity transaction totaling million the effective tax rate in both and wa also affected by relatively significant earnings in lower tax jurisdiction due primarily to the non deductibility of intangible asset amortization for tax purpose the company cash payment for income tax were higher than it income tax expense for financial reporting purpose and totaled billion and billion in and respectively the company expects it gaap effective tax rate in will be and based on currently forecasted rate of profitability in the country in which the company conduct business and expected generation of foreign tax credit the effective tax rate can vary significantly from period to period result of discrete income tax factor and event the company expects it adjusted tax rate will be approximately in the company ha operation and taxable presence in approximately country outside the some of these country have lower tax rate than the the company ability to obtain benefit from lower tax rate outside the is dependent on it relative level of income in country outside the and on the statutory tax rate in those country based on the dispersion of the company non income tax provision among many country the company belief that change in the statutory tax rate in any individual country is not likely to materially affect the company income tax provision or net income aside from any resulting one time adjustment to the company deferred tax balance to reflect new rate liquidity and capital resourcesthe company proven growth strategy ha enabled it to generate free cash flow well access the capital market the company deploys it capital primarily via merger and acquisition and secondarily via share buyback and dividend december december in million and cash equivalent total approximately half of the company cash balance and cash flow from operation are from outside the the company us it non cash for need outside of the including acquisition capacity expansion and repayment of third party foreign debt by foreign subsidiary in addition the company also transfer cash to the using non taxable return of capital well dividend where the related dividend received deduction or foreign tax credit equal any tax cost arising from the dividend result of using such mean of transferring cash to the the company doe not expect any material adverse liquidity effect from it significant non cash balance for the foreseeable future the company belief that it existing cash and cash equivalent and it future cash flow from operation together with available borrowing capacity under it revolving credit agreement will be sufficient to meet the cash requirement of it existing business for the foreseeable future including at least the next month of december the company short term debt totaled billion the company ha revolving credit facility with bank group that provides up to billion of unsecured multi currency revolving credit note if the company borrows under this facility it intends to leave undrawn an amount equivalent to outstanding commercial paper to provide source of fund in the event that commercial paper market are not available of december no borrowing were outstanding under the company revolving credit facility although available capacity wa reduced by immaterial outstanding letter of credit fisher scientific inc in million cash provided by operating activity net cash used in investing activity net cash used in provided by financing activity free cash flow non gaap measure operating activitiesduring cash provided by income wa offset in part by investment in working capital increase in account receivable and inventory used cash of billion and billion respectively primarily to support growth in sale an increase in account payable provided cash of billion cash payment for income tax were billion during during cash provided by income wa offset in part by investment in working capital increase in account receivable and inventory used cash of billion and billion respectively primarily to support growth in sale an increase in account payable provided cash of billion change in other asset and other liability used cash of billion primarily due to the timing of tax and incentive compensation payment cash payment for income tax were billion during the company is contingently liable with respect to certain legal proceeding and related matter an unfavorable outcome that differs materially from current accrual estimate if any for one or more of the matter described under the heading product liability worker compensation and other personal injury matter in note could have material adverse effect on the company financial position well it result of operation and cash flow investing activitiesduring acquisition used cash of billion the company investing activity were principally for the purchase of property plant and equipment for capacity and capability investment during acquisition used cash of billion the company investing activity also included the purchase of billion of property plant and equipment the company expects that for all of expenditure for property plant and equipment net of disposal will be approximately billion financing activitiesduring issuance of senior note provided billion in cash repayment of senior note and net commercial paper activity used cash of billion and billion respectively the company financing activity also included the repurchase of billion of the company common stock million share and the payment of billion in cash dividend on september the board of director authorized the repurchase of up to billion of the company common stock all of the share of common stock repurchased by the company during the fourth quarter of were purchased under this program depleting the authorization on november the board of director authorized the repurchase of up to billion of the company common stock early in the first quarter of the company repurchased billion of the company common stock million share at february authorization remained for billion of future repurchase of the company common stock during issuance of senior note provided billion of cash net increase in commercial paper obligation provided cash of billion repayment of debt used cash of billion including billion to repay the debt assumed in the acquisition of ppd the company financing activity also included the repurchase of billion of the company common stock million share and the payment of billion in cash dividend in addition to the obligation on the balance sheet at december which include but are not limited to debt note unrecognized tax benefit note operating lease note pension obligation note and contingent consideration note the company ha entered into unconditional purchase obligation in the ordinary course of business that include agreement to purchase good service or fixed asset and to pay royalty note non gaap measuresin addition to the financial measure prepared in accordance with generally accepted accounting principle gaap we use certain non gaap financial measure such organic revenue growth which is reported revenue growth excluding the impact of revenue from acquired divested business and the effect of currency translation we report organic revenue growth because thermo fisher management belief that in order to understand the company short term and long term financial trend investor may wish to consider the impact of acquisition divestiture and foreign currency translation on fisher scientific inc revenue thermo fisher management us organic revenue growth to forecast and evaluate the operational performance of the company well to compare revenue of current period to prior period we report adjusted operating income adjusted operating income margin adjusted other income expense adjusted tax rate and adjusted eps we believe that the use of these non gaap financial measure in addition to gaap financial measure help investor to gain better understanding of our core operating result and future prospect consistent with how management measure and forecast the company core operating performance especially when comparing such result to previous period forecast and to the performance of our competitor such measure are also used by management in their financial and operating decision making and for compensation purpose to calculate these measure we exclude applicable certain acquisition related cost including charge for the sale of inventory revalued at the date of acquisition significant transaction acquisition related cost including change in estimate of contingent acquisition related consideration and other cost associated with obtaining short term financing commitment for pending recent acquisition we exclude these cost because we do not believe they are indicative of our normal operating cost cost income associated with restructuring activity and large scale abandonment of product line such reducing overhead and consolidating facility we exclude these cost because we believe that the cost related to restructuring activity and large scale abandonment of product line are not indicative of our normal operating cost equity in earnings loss of unconsolidated entity impairment of long lived asset and certain other gain and loss that are either isolated or can not be expected to occur with any predictability including gain loss on investment the sale of business product line and real estate significant litigation related matter curtailment settlement of pension plan and the early retirement of debt we exclude these item because they are outside of our normal operation and or in certain case are difficult to forecast accurately for future period the expense associated with the amortization of acquisition related intangible asset because significant portion of the purchase price for acquisition may be allocated to intangible asset that have life of up to year exclusion of the amortization expense allows comparison of operating result that are consistent over time for both our newly acquired and long held business and with both acquisitive and non acquisitive peer company the tax impact of the above item and the impact of significant tax audit or event such change in deferred tax from enacted tax rate law change the latter of which we exclude because they are outside of our normal operation and difficult to forecast accurately for future period we report free cash flow which is operating cash flow excluding net capital expenditure to provide view of the continuing operation ability to generate cash for use in acquisition and other investing and financing activity the company also us this measure an indication of the strength of the company free cash flow is not measure of cash available for discretionary expenditure since we have certain non discretionary obligation such debt service that are not deducted from the measure the non gaap financial measure of the company result of operation and cash flow included in this form are not meant to be considered superior to or substitute for the company result of operation prepared in accordance with gaap reconciliation of such non gaap financial measure to the most directly comparable gaap financial measure are set forth within the overview and result of operation section and below dollar in million except per share amount of adjusted operating income and adjusted operating income margingaap operating income cost of revenue adjustment selling general and administrative expense adjustment restructuring and other cost amortization of acquisition related intangible adjusted operating income non gaap measure reconciliation of adjusted other income expense gaap other income expense adjustment adjusted other income expense non gaap measure fisher scientific inc dollar in million except per share amount of adjusted tax rategaap tax adjustment adjusted tax rate non gaap measure reconciliation of adjusted earnings per sharegaap diluted earnings per share eps attributable to thermo fisher scientific inc cost of revenue adjustment selling general and administrative expense adjustment restructuring and other cost amortization of acquisition related intangible other income expense adjustment provision for income tax adjustment equity in earnings loss of unconsolidated adjusted eps non gaap measure reconciliation of free cash flowgaap net cash provided by operating activity purchase of property plant and equipment proceeds from sale of property plant and free cash flow non gaap measure adjusted result exclude charge for the sale of inventory revalued at the date of acquisition adjusted result in also exclude million of inventory write down associated with large scale abandonment of product line adjusted result exclude certain third party expense principally transaction integration cost related to recent acquisition charge credit for change in estimate of contingent acquisition consideration and charge associated with product liability litigation adjusted result exclude restructuring and other cost consisting principally of severance impairment of long lived asset charge credit for environmental related matter abandoned facility and other expense of headcount reduction within several business and real estate consolidation adjusted result in also exclude million of gain on the sale of intellectual property adjusted result in also exclude million of charge for impairment of acquired intangible asset and million of charge for compensation due to employee at recently acquired business at the date of acquisition adjusted result exclude net gain loss on investment and loss on the early extinguishment of debt adjusted result in also exclude million of net gain on derivative instrument to address certain foreign currency risk and million of net settlement gain for pension plan adjusted result in also exclude million of charge for amortization of bridge loan commitment fee related to pending acquisition adjusted provision for income tax excludes incremental tax impact for the reconciling item between gaap and adjusted net income incremental tax impact result of tax rate law change and the tax impact from audit settlement including million benefit from an audit settlement in adjusted result in also exclude million charge for the impact of deferred tax realizability assessment result of audit settlement critical accounting policy and estimatesthe company discussion and analysis of it financial condition and result of operation is based upon it financial statement which have been prepared in accordance with accounting principle generally accepted in the united state of america the preparation of these financial statement requires management to make estimate and assumption that affect the reported amount of asset liability revenue and expense and related disclosure of contingent liability on an on going basis management evaluates it estimate including those related to acquisition related measurement and income tax management belief the most complex and sensitive judgment because of their significance to the consolidated financial statement result primarily from the need to make estimate about the effect of matter that are inherently uncertain management base it estimate on historical experience current market and economic condition and other assumption that management belief are reasonable the result of these estimate form the basis for judgment about the carrying value of asset and liability where the value are not readily apparent from other source actual result may differ from these estimate under different assumption or condition fisher scientific inc the company belief the following represent it critical accounting policy and estimate used in the preparation of it financial statement acquisition related measurement business combinationsthe company us assumption and estimate in determining the fair value of asset acquired and liability assumed in business combination the determination of the fair value of intangible asset which represent significant portion of the purchase price in many of the company acquisition requires the use of significant judgment with regard to the fair value and ii whether such intangible are amortizable or non amortizable and if the former the period and the method by which the intangible asset will be amortized the company estimate the fair value of acquisition related intangible asset principally based on projection of cash flow that will arise from identifiable intangible asset of acquired business which include estimate of customer attrition and technology obsolescence rate the projected cash flow are discounted to determine the present value of the asset at the date of acquisition see note for additional information about our recent business combination goodwill and indefinite lived intangible assetsthe company evaluates goodwill and indefinite lived intangible asset for impairment annually and when event occur or circumstance change that would more likely than not reduce the fair value of an asset below it carrying amount event or circumstance that might require an interim evaluation include unexpected adverse business condition economic factor unanticipated technological change or competitive activity loss of key personnel and act by government and court among others goodwill and indefinite lived intangible asset totaled billion and billion respectively at december see note for additional information estimate of discounted future cash flow require assumption related to revenue and operating income growth rate discount rate and other factor for the goodwill impairment test the company also considers peer revenue and earnings trading multiple from company that have operational and financial characteristic that are similar to the respective reporting unit and ii estimated weighted average cost of capital different assumption from those made in the company analysis could materially affect projected cash flow and the company evaluation of goodwill and indefinite lived intangible asset for impairment except described below the company performed the quantitative goodwill impairment test for all of it reporting unit and indefinite lived intangible asset determination of fair value based on projection of discounted cash flow which decreased from the prior year projection primarily due to higher discount rate and based on peer revenue and earnings trading multiple which also decreased from the prior year were sufficient to conclude that no impairment of goodwill or indefinite lived intangible asset existed at the end of the tenth fiscal month of the date of the company annual impairment testing there were no interim impairment of goodwill or indefinite lived intangible asset in there can be no assurance however that adverse event or condition will not cause the fair value of these asset to decline should the fair value of the company reporting unit or indefinite lived intangible asset decline because of reduced operating performance market decline or other indicator of impairment or result of change in the discount rate charge for impairment may be necessary with the completion of the ppd acquisition in december the company established two new reporting unit that solely consist of the legacy ppd business the book carrying value of which equaled their fair value of the acquisition date during it annual goodwill impairment assessment the company performed qualitative assessment of these reporting unit and determined that no event had occurred and no circumstance had changed that would more likely than not reduce the fair value of the reporting unit below their carrying amount result the company did not perform the quantitative goodwill impairment test for these reporting unit given that the fair value of the reporting unit were unlikely to be substantially in excess of their carrying value of the annual assessment date relatively small decrease in future cash flow versus anticipated result decrease in peer trading multiple and or increase in weighted average cost of capital could result in impairment of goodwill the reporting unit consisting of the legacy ppd business had billion of goodwill and an overall carrying value of billion of december definite lived intangible assetsdefinite lived intangible asset totaled billion at december see note for additional information certain definite lived intangible asset have largely independent cash flow the company review these definite lived intangible asset for impairment individually when indication of potential impairment exists such significant reduction in cash flow associated with the asset actual cash flow arising from particular intangible asset could vary from projected cash flow which could imply different carrying value from those established at the date of acquisition and which could result in impairment of such asset most of the company definite lived intangible asset are used in conjunction with other asset such property plant and equipment and operating lease right of use asset in these situation the company considers fisher scientific inc the asset group to be the unit of account for impairment testing the company recorded impairment of billion in see note income taxesunrecognized tax benefitsin the ordinary course of business there is inherent uncertainty in quantifying the company income tax position the company ass income tax position and record tax benefit for all year subject to examination based upon management evaluation of the fact circumstance and information available at the reporting date for those tax position where it is more likely than not that tax benefit will be sustained the company ha recorded the largest amount of tax benefit with greater than percent likelihood of being realized upon ultimate settlement with taxing authority that ha full knowledge of all relevant information for those income tax position where it is not more likely than not that tax benefit will be sustained no tax benefit ha been recognized in the financial statement should tax return position that the company expects are sustainable not be sustained upon audit the company could be required to record an incremental tax provision for such tax the company liability for these unrecognized tax benefit totaled billion at december compared to billion at december primarily result of an audit settlement see note the company operates in numerous country under many legal form and result is subject to the jurisdiction of numerous domestic and non tax authority well to tax agreement and treaty among these government determination of taxable income in any jurisdiction requires the company to interpret the related tax law and regulation and the use of estimate and assumption regarding significant future event such the amount timing and character of deduction permissible revenue recognition method under the tax law and the source and character of income and tax credit change in tax law regulation agreement and treaty currency exchange restriction or the company level of operation or profitability in each taxing jurisdiction could have an impact upon the amount of current and deferred tax balance and hence the company net income valuation allowancesthe company estimate the degree to which tax asset will result in benefit after consideration of all positive and negative evidence and provides valuation allowance for tax asset that it belief will more likely than not go unused in situation in which the company ha been able to determine that it deferred tax asset will be realized that determination generally relies on future reversal of taxable temporary difference and expected future taxable income if it becomes more likely than not that tax asset will be used the company revers the related valuation allowance any such reversal are recorded reduction of the company tax provision the company tax valuation allowance totaled billion at december compared to billion at december primarily driven by the assessment of additional tax asset resulting from an audit settlement during the year see note should the company actual future taxable income by tax jurisdiction vary from estimate additional allowance or reversal thereof may be necessary recent accounting pronouncementsa description of recently issued accounting standard is included under the heading recent accounting pronouncement in note item quantitative and qualitative disclosure about market riskthe company is exposed to market risk from change in interest rate and currency exchange rate which could affect it future result of operation and financial condition the company manages it exposure to these risk through it regular operating and financing activity the company ha periodically hedged interest rate risk of fixed rate instrument with offsetting interest rate swap additionally the company us short term forward and option contract primarily to hedge certain balance sheet and operational exposure resulting from change in currency exchange rate such exposure result from purchase sale cash and intercompany loan that are denominated in currency other than the functional currency of the respective operation the currency exchange contract principally hedge transaction denominated in euro british pound sterling singapore dollar japanese yen hong kong dollar czech koruna and swedish krona income and loss arising from these derivative contract are recognized offset to loss and income resulting from the underlying exposure being hedged the company doe not enter into speculative derivative agreement interest ratesthe company is exposed to change in interest rate while conducting normal business operation result of ongoing investing and financing activity which affect the company debt well cash and cash equivalent of december the company debt portfolio wa comprised primarily of fixed rate borrowing the fair market value of the company fixed interest rate debt is subject to interest rate risk generally the fair market value of fixed interest rate debt will increase fisher scientific inc interest rate fall and decrease interest rate rise the total estimated fair value of the company debt at december wa billion note fair value were determined from available market price using current interest rate and term to maturity if interest rate were to decrease by basis point the fair value of the company debt at december would increase by approximately billion if interest rate were to increase by basis point the fair value of the company debt at december would decrease by approximately billion in addition interest rate change would result in change in the company interest expense due to variable rate debt instrument including swap arrangement in basis point increase in interest rate on the swap arrangement and variable rate debt would have increased the company annual pre tax interest expense by approximately million currency exchange ratesthe company view it investment in international subsidiary with functional currency other than the dollar permanent the company investment in international subsidiary is sensitive to fluctuation in currency exchange rate the functional currency of the company international subsidiary are principally denominated in euro british pound sterling swedish krona canadian dollar norwegian krone and danish krone the effect of change in the period ending currency exchange rate on the company net investment in international subsidiary is reflected in the accumulated other comprehensive item component of shareholder equity the company also us foreign currency denominated debt to partially hedge it net investment in foreign operation against adverse movement in exchange rate depreciation in year end functional currency relative to the dollar would result in reduction of shareholder equity of approximately billion the fair value of forward currency exchange contract is sensitive to change in currency exchange rate the fair value of forward currency exchange contract is the estimated amount that the company would pay or receive upon termination of the contract taking into account the change in currency exchange rate depreciation in year end non functional currency exchange rate related to the company contract would result in an additional unrealized loss on forward currency exchange contract of million appreciation in year end non functional currency exchange rate related to the company contract would result in an unrealized gain on forward currency exchange contract of million the unrealized gain or loss on forward currency exchange contract resulting from change in currency exchange rate are expected to approximately offset loss or gain on the exposure being hedged certain of the company cash and cash equivalent are denominated in currency other than the functional currency of the depositor and are sensitive to change in currency exchange rate depreciation in the related year end non functional currency exchange rate applied to such cash balance would result in negative impact of million on the company net income item financial statement and supplementary datathis data is submitted separate section to this report see item exhibit and financial statement schedule item change in and disagreement with accountant on accounting and financial disclosurenot applicable item control and proceduresmanagement evaluation of disclosure control and proceduresthe company management with the participation of the company chief executive officer and chief financial officer ha evaluated the effectiveness of the company disclosure control and procedure such term is defined in rule and under the exchange act of the end of the period covered by this report management recognizes that any control and procedure no matter how well designed and operated can provide only reasonable assurance of achieving their objective and management necessarily applies it judgment in evaluating the cost benefit relationship of possible control and procedure based on such evaluation the company chief executive officer and chief financial officer concluded that of the end of such period the company disclosure control and procedure were effective at the reasonable assurance level change in internal control over financial reportingthere have been no change in the company internal control over financial reporting defined in exchange act rule and during the fiscal quarter ended december that have materially affected or are reasonably likely to materially affect the company internal control over financial reporting fisher scientific inc management annual report on internal control over financial reportingthe company management including the company chief executive officer and chief financial officer is responsible for establishing and maintaining adequate internal control over financial reporting defined in exchange act rule and for the company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle the company management conducted an assessment of the effectiveness of the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso based on this assessment the company management concluded that of december the company internal control over financial reporting wa effective the company independent registered public accounting firm pricewaterhousecoopers llp ha audited the effectiveness of the company internal control over financial reporting of december stated in their report that appears on page of this annual report on form item other informationon february the board of director of the company amended and restated the company by law effective immediately to conform the by law to the security and exchange commission universal proxy rule contained in rule under the security exchange act of and certain amendment to the general corporation law of the state of delaware the dgcl the amendment to the by law include addition to article section to implement the requirement of rule regarding the nomination and solicitation of proxy for director candidate the amendment to the by law also include revision to article section and to conform with the dgcl amendment the foregoing description of the amendment to the by law doe not purport to be complete and is qualified in it entirety by reference to the full text of the by law amended and restated copy of which is attached exhibit and incorporated by reference herein on february the company entered into consulting agreement with mark stevenson former executive vice president and chief operating officer of the company relating to service that mr stevenson will provide to the company under the consulting agreement which ha term ending march mr stevenson will serve on the company scientific advisory board and will also provide ongoing advice and service requested by the company during the term of the consulting agreement mr stevenson will receive compensation of per month the agreement also contains provision that restrict mr stevenson ability during the term of the consulting agreement to work for or provide consulting service to any competitor of the company and ii to solicit for hire employee or consultant of the company or to solicit customer or client of the company item disclosure regarding foreign jurisdiction that prevent inspectionsnot applicable part iiiitem director executive officer and corporate governancethe information with respect to director required by this item will be contained in our definitive proxy statement to be filed with the sec not later than day after the close of business of the fiscal year definitive proxy statement including under corporate governance and is incorporated in this report by reference the information with respect to executive officer required by this item is included in item of part of this report the other information required by this item will be contained in our definitive proxy statement including under corporate governance and is incorporated in this report by reference item executive compensationthe information required by this item will be contained in our definitive proxy statement including under corporate governance and executive compensation and is incorporated in this report by reference item security ownership of certain beneficial owner and management and related stockholder mattersthe information required by this item will be contained in our definitive proxy statement including under information about stock ownership and is incorporated in this report by reference fisher scientific inc item certain relationship and related transaction and director independencethe information required by this item will be contained in our definitive proxy statement including under corporate governance and is incorporated in this report by reference item principal accountant fee and servicesthe information required by this item will be contained in our definitive proxy statement including under audit matter and is incorporated in this report by reference part ivitem exhibit and financial statement schedule the following document are filed part of this report consolidated financial statement see index on page of this report report of independent registered public accounting firmconsolidated balance sheetconsolidated statement of incomeconsolidated statement of comprehensive incomeconsolidated statement of cash flowsconsolidated statement of redeemable noncontrolling interest and equitynotes to consolidated financial statement all schedule are omitted because they are not applicable or not required or because the required information is included either in the consolidated financial statement or in the note thereto exhibitssee the exhibit index on page item form summarynone fisher scientific inc exhibit indexexhibit numberdescription of and plan of merger dated of april by and among thermo fisher scientific inc powder acquisition corp and ppd inc filed exhibit to the registrant current report on form filed april file no and incorporated in this document by reference and restated certificate of incorporation of the registrant filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference to thermo fisher scientific inc third amended and restated certificate of incorporation filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference of elimination of the series junior participating preferred stock of the company dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference and restated by law of the registrant amended and effective of february registrant agrees pursuant to item iii of regulation to furnish to the commission upon request copy of each instrument with respect to long term debt of the registrant or it consolidated subsidiary dated of november between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference supplemental indenture dated of december between the company and the bank of new york mellon trust company filed exhibit to the registrant current report on form filed december file no and incorporated in this document by reference supplemental indenture dated of november among the company the bank of new york mellon trust company trustee and the bank of new york mellon london branch paying agent filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference supplemental indenture dated of september between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed september file no and incorporated in this document by reference supplemental indenture dated of march between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed march file no and incorporated in this document by reference supplemental indenture dated of july between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed july file no and incorporated in this document by reference supplemental indenture dated of august between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed august file no and incorporated in this document by reference supplemental indenture dated of september between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed september file no and incorporated in this document by reference supplemental indenture dated of october between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed october file no and incorporated in this document by reference first supplemental indenture dated of april between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed april file no and incorporated in this document by reference second supplemental indenture dated of august between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed august file no and incorporated in this document by reference third supplemental indenture dated of october between the company and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed october file no and incorporated in this document by reference fourth supplemental indenture dated of october between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed october file no and incorporated in this document by reference fifth supplemental indenture dated of november between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference sixth supplemental indenture dated of november between the company issuer and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of dated of august among thermo fisher international issuer the company guarantor and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed august file no and incorporated in this document by reference supplemental indenture dated of october among thermo fisher scientific finance thermo fisher international issuer the company guarantor and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed october file no and incorporated in this document by reference supplemental indenture dated of november among thermo fisher scientific finance thermo fisher international issuer the company guarantor and the bank of new york mellon trust company trustee filed exhibit to the registrant current report on form filed august file no and incorporated in this document by reference of the registrant fisher scientific inc deferred compensation plan for director of the registrant amended and restated effective november filed exhibit to the registrant quarterly report on form for the quarter ended september file no and incorporated in this document by reference electron corporation deferred compensation plan effective november filed exhibit to the registrant annual report on form for the fiscal year ended december file no and incorporated in this document by reference of amended and restated indemnification agreement between the registrant and it director and officer filed exhibit to the registrant registration statement on form reg no and incorporated in this document by reference of thermo fisher scientific inc annual non management director compensation filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference of noncompetition agreement between the registrant and certain key employee and executive officer effective of january filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference plan for non employee director of fisher scientific international inc filed exhibit to fisher scientific international inc annual report on form for the year ended december file no and incorporated in this document by reference amendment to the fisher scientific international inc retirement plan for non employee director filed exhibit to fisher scientific international inc quarterly report on form for the quarter ended march file no and incorporated in this document by reference to retirement plan for non employee director of fisher scientific international inc filed exhibit to fisher scientific international inc current report on form filed march file no and incorporated in this document by reference fisher scientific inc amended and restated deferred compensation plan effective january filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference restatement of executive severance agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference change in control retention agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference agreement between marc casper and the registrant dated november filed exhibit to the registrant current report on form filed november file no and incorporated in this document by reference no to restatement of executive severance agreement dated february between the registrant and marc casper filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference no to restatement of executive severance agreement dated november between the registrant and marc casper filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference no to executive change in control retention agreement dated november between marc casper and the registrant filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference no to executive change in control retention agreement dated march between marc casper and the registrant filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of of executive change in control retention agreement for officer other than marc casper filed exhibit to the registrant quarterly report on form for the quarter ended march file no and incorporated in this document by reference of thermo fisher scientific inc restricted stock unit agreement for director filed exhibit to the registrant quarterly report on form for the quarter ended april file no and incorporated in this document by reference of nonstatutory stock option agreement between thermo fisher scientific inc and marc casper effective february filed exhibit to the registrant current report on form filed february file no and incorporated in this document by reference fisher scientific inc stock incentive plan filed exhibit to the registrant current report on form filed may file no and incorporated in this document by reference executive retirement plan effective of december amended and restated of august filed exhibit to applera corporation quarterly report on form for the quarter ended september file no and incorporated in this document by reference to supplemental executive retirement plan effective of january filed exhibit to life technology corporation current report on form filed december file no and incorporated in this document by reference agreement between the registrant and mark stevenson dated september filed exhibit to the registrant quarterly report on form for the quarter ended september file no and incorporated in this document by reference of thermo fisher scientific inc nonstatutory stock option agreement for officer filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference omnibus incentive plan filed exhibit to the current report on form filed by patheon on july file no and incorporated in this document by reference to patheon omnibus incentive plan dated march filed exhibit to the registrant registration statement on form filed august file no and incorporated in this document by reference to patheon omnibus incentive plan dated august filed exhibit to the registrant registration statement on form filed august file no and incorporated in this document by reference agreement dated january among thermo fisher scientific inc certain subsidiary of thermo fisher scientific inc from time to time party thereto bank of america administrative agent and each lender from time to time party thereto filed exhibit to the registrant current report on form filed january file no and incorporated in this document by reference agreement between the registrant and michel lagarde dated august filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference agreement under the patheon omnibus incentive plan between patheon and michel lagarde dated july filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference agreement under the patheon omnibus incentive plan between patheon and michel lagarde dated march filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference fisher scientific inc executive severance policy filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference of noncompetition agreement between the registrant and certain key employee and executive officer filed exhibit to the registrant quarterly report on form for the quarter ended june file no and incorporated in this document by reference of thermo fisher scientific inc performance restricted stock unit agreement effective of february filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of thermo fisher scientific inc restricted stock unit agreement effective of february filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of thermo fisher scientific inc nonstatutory stock option agreement for officer effective of february filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference fisher scientific inc exhibit indexexhibit numberdescription of of performance restricted stock unit agreement between thermo fisher scientific inc and marc casper effective of february filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of restricted stock unit agreement between thermo fisher scientific inc and marc casper effective of february filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of nonstatutory stock option agreement between thermo fisher scientific inc and marc casper effective of february filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of restricted stock unit agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of performance restricted stock unit agreement between thermo fisher scientific inc and marc casper filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference of thermo fisher scientific inc performance restricted stock unit agreement filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference inc omnibus incentive plan filed exhibit to ppd inc form filed january file no and incorporated in this document by reference agreement between the registrant and mark stevenson dated february filed exhibit to the registrant annual report on form for the year ended december file no and incorporated in this document by reference to nonstatutory stock option agreement between thermo fisher scientific inc and marc casper to restricted stock unit agreement between thermo fisher scientific inc and marc casper to performance restricted stock unit agreement between thermo fisher scientific inc and marc casper of the registrant issuer of guaranteed security of pricewaterhousecoopers llp an independent registered public accounting firm of chief executive officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief financial officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief executive officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of of chief financial officer required by exchange act rule and adopted pursuant to section of the sarbanes oxley act of insxbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document schxbrl taxonomy extension schema document calxbrl taxonomy calculation linkbase document defxbrl taxonomy definition linkbase document labxbrl taxonomy label linkbase document prexbrl taxonomy presentation linkbase document page interactive data file formatted inline xbrl and contained in exhibit _______________________ indicates management contract or compensatory plan contract or arrangement certification is not deemed filed for purpose of section of the exchange act or otherwise subject to the liability of that section such certification is not deemed to be incorporated by reference into any filing under the security act or the exchange act except to the extent that the registrant specifically incorporates it by reference to the requirement of section or of the security exchange act of the registrant ha duly caused this report to be signed on it behalf by the undersigned thereunto duly authorized date february fisher scientific inc by marc caspermarc casperchairman president and chief executive officerpursuant to the requirement of the security exchange act of this report ha been signed below by the following person on behalf of the registrant and in the capacity indicated of february by marc casperby alexandra keithmarc casperr alexandra keithchairman president and chief executive officerdirector principal executive officer by stephen williamsonby jim manzistephen williamsonjim manzisenior vice president and chief financial officerdirector principal financial officer by joseph holmesby james mullenjoseph holmesjames mullenvice president and chief accounting officerdirector principal accounting officer by nelson chaiby lars srensennelson chailars srensendirectordirectorby ruby chandyby debora sparruby chandydebora spardirectordirectorby martin harrisby scott sperlingc martin harrisscott sperlingdirectordirectorby tyler jacksby dion weislertyler jacksdion fisher scientific inc index of consolidated financial statement the following consolidated financial statement of the registrant and it subsidiary are required to be included in item page report of independent registered public accounting firm pcaob id balance sheet of december and statement of income for the year ended december and statement of comprehensive income for the year ended december and statement of cash flow for the year ended december and statement of redeemable noncontrolling interest and equity for the year ended december and to consolidated financial statementsf of independent registered public accounting firmto the board of director and shareholder of thermo fisher scientific inc opinion on the financial statement and internal control over financial reportingwe have audited the accompanying consolidated balance sheet of thermo fisher scientific inc and it subsidiary the company of december and and the related consolidated statement of income of comprehensive income of redeemable noncontrolling interest and equity and of cash flow for each of the three year in the period ended december including the related note collectively referred to the consolidated financial statement we also have audited the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission coso in our opinion the consolidated financial statement referred to above present fairly in all material respect the financial position of the company of december and and the result of it operation and it cash flow for each of the three year in the period ended december in conformity with accounting principle generally accepted in the united state of america also in our opinion the company maintained in all material respect effective internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the coso basis for opinionsthe company management is responsible for these consolidated financial statement for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in management annual report on internal control over financial reporting appearing under item our responsibility is to express opinion on the company consolidated financial statement and on the company internal control over financial reporting based on our audit we are public accounting firm registered with the public company accounting oversight board united state pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statement are free of material misstatement whether due to error or fraud and whether effective internal control over financial reporting wa maintained in all material respect our audit of the consolidated financial statement included performing procedure to ass the risk of material misstatement of the consolidated financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the consolidated financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the consolidated financial statement our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk our audit also included performing such other procedure we considered necessary in the circumstance we believe that our audit provide reasonable basis for our opinion definition and limitation of internal control over financial reportinga company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company ii provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and iii provide reasonable assurance regarding prevention or timely of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate critical audit mattersthe critical audit matter communicated below is matter arising from the current period audit of the consolidated financial statement that wa communicated or required to be communicated to the audit committee and that relates to account or disclosure that are material to the consolidated financial statement and ii involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which it relates income taxesas described in note to the consolidated financial statement the company provision for income tax for the year ended december wa million the company ha deferred tax liability net of million including valuation allowance of million and unrecognized tax benefit of million of december disclosed by management the company operates in numerous country under many legal form and result is subject to the jurisdiction of numerous domestic and non tax authority well to tax agreement and treaty among these government determination of taxable income in any jurisdiction requires management to interpret the related tax law and regulation and to use estimate and assumption regarding significant future event such the amount timing and character of deduction permissible revenue recognition method under the tax law and the source and character of income and tax credit management ass income tax position and record tax benefit for all year subject to examination based upon management evaluation of the fact circumstance and information available at the reporting date for those tax position where it is more likely than not that tax benefit will be sustained management ha recorded the largest amount of tax benefit with greater than percent likelihood of being realized upon ultimate settlement with taxing authority that ha full knowledge of all relevant information for those income tax position where it is not more likely than not that tax benefit will be sustained no tax benefit ha been recognized in the financial statement management estimate the degree to which tax asset will result in benefit after consideration of all positive and negative evidence and provides valuation allowance for tax asset that it belief will more likely than not go unused in situation in which management ha been able to determine that the company deferred tax asset will be realized that determination generally relies on future reversal of taxable temporary difference and expected future taxable income if it becomes more likely than not that tax asset will be used management revers the related valuation allowance the principal consideration for our determination that performing procedure relating to income tax is critical audit matter are the significant judgment by management when interpreting the numerous and complex tax law and regulation it relates to determining the provision for income tax deferred tax asset and liability including the valuation allowance and liability for unrecognized tax benefit ii high degree of auditor judgment subjectivity and effort in performing procedure and evaluating audit evidence related to the provision for income tax deferred tax asset and liability including the valuation allowance and liability for unrecognized tax benefit and iii the audit effort involved the use of professional with specialized skill and knowledge addressing the matter involved performing procedure and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statement these procedure included testing the effectiveness of control relating to the provision for income tax deferred tax asset and liability including the valuation allowance and liability for unrecognized tax benefit these procedure also included among others testing the accuracy of the provision for income tax including the rate reconciliation and permanent and temporary difference ii evaluating whether the data utilized in the calculation of the provision for income tax deferred tax asset and liability and liability for unrecognized tax benefit were appropriate and consistent with evidence obtained in other area of the audit iii evaluating management assessment of the realizability of deferred tax asset on jurisdictional basis iv the identification of liability for unrecognized tax benefit and the reasonableness of the more likely than not determination in consideration of court decision legislative action statute of limitation and development in tax examination by jurisdiction testing the calculation of the liability for unrecognized tax benefit by jurisdiction including estimate of the amount of income tax benefit expected to be sustained and vi evaluating the adequacy of the company disclosure professional with specialized skill and knowledge were used to assist in evaluating the reasonableness of management judgment and estimate related to the application of foreign and domestic tax law and regulation pricewaterhousecoopers llpboston massachusettsfebruary we have served the company auditor since fisher scientific inc consolidated balance sheet december december in million except share and per share amount asset cash and cash equivalent account receivable le allowance of and contract asset other current total current property plant and equipment acquisition related intangible asset other total asset liability redeemable noncontrolling interest and equitycurrent liability short term obligation and current maturity of long term obligation account accrued payroll and employee contract other accrued total current deferred income other long term long term commitment and contingency note redeemable noncontrolling equity thermo fisher scientific inc shareholder equity preferred stock par value share authorized none issuedcommon stock par value share authorized and share capital in excess of par retained treasury stock at cost and share accumulated other comprehensive item total thermo fisher scientific inc shareholder noncontrolling total total liability redeemable noncontrolling interest and equity the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of income year ended december december december in million except per share amount revenue service total cost and operating expense cost of product cost of service selling general and administrative research and development restructuring and other total cost and operating operating interest interest expense other income expense income before income provision for income tax equity in earnings loss of unconsolidated entity net le net income attributable to noncontrolling interest and redeemable noncontrolling net income attributable to thermo fisher scientific inc earnings per share attributable to thermo fisher scientific inc basic diluted weighted average the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of comprehensive income year ended december december december in million incomenet income other comprehensive item currency translation adjustment currency translation adjustment net of tax provision benefit of and unrealized gain and loss on hedging instrument unrealized loss on hedging instrument net of tax benefit of and reclassification adjustment for loss included in net income net of tax benefit of and pension and other postretirement benefit liability adjustment pension and other postretirement benefit liability adjustment arising during the period net of tax provision benefit of and amortization of net loss and prior service benefit included in net periodic pension cost net of tax benefit of and total other comprehensive item comprehensive le comprehensive income attributable to noncontrolling interest and redeemable noncontrolling comprehensive income attributable to thermo fisher scientific inc the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of cash flowsyear endeddecember december december in million activitiesnet income adjustment to reconcile net income to net cash provided by operating activity depreciation of property plant and amortization of acquisition related intangible change in deferred income tax stock based loss on early extinguishment of other non cash change in asset and liability excluding the effect of acquisition and disposition account receivable inventory account contribution to retirement plan other net cash provided by operating investing activity acquisition net of cash acquired purchase of property plant and equipment proceeds from sale of property plant and other investing activity net cash used in investing activity financing activitiesnet proceeds from issuance of repayment of debt proceeds from issuance of commercial repayment of commercial paper purchase of company common stock dividend paid other financing activity net net cash used in provided by financing activity exchange rate effect on cash increase decrease in cash cash equivalent and restricted cash cash equivalent and restricted cash at beginning of cash cash equivalent and restricted cash at end of year the accompanying note are an integral part of these consolidated financial statement fisher scientific inc consolidated statement of redeemable noncontrolling interest and equity redeemable noncontrolling interestcommon stockcapital in excess of par valueretained earningstreasury stockaccumulated other comprehensive itemstotal thermo fisher scientific inc shareholder equitynoncontrolling intereststotal equity in million sharesamountsharesamountbalance at december cumulative effect of accounting change issuance of share under employee and director stock plan stock based compensation purchase of company common stock dividend declared per share net income other comprehensive item contribution from distribution to noncontrolling interest balance at december issuance of share under employee and director stock plan stock based compensation purchase of company common stock dividend declared per share recognition upon net other comprehensive item contribution from distribution to noncontrolling interest other balance at december issuance of share under employee and director stock plan stock based compensation purchase of company common stock dividend declared per share net other comprehensive item contribution from distribution to noncontrolling interest balance at december the accompanying note are an integral part of these consolidated financial statement fisher scientific inc note to consolidated financial statementsnote nature of operation and summary of significant accounting policy nature of operationsthermo fisher scientific inc the company or thermo fisher enables customer to make the world healthier cleaner and safer by helping them accelerate life science research solve complex analytical challenge increase laboratory productivity and improve patient health through diagnostics and the development and manufacture of life changing therapy market served include pharmaceutical and biotech academic and government industrial and applied well healthcare and diagnostics principle of consolidationthe accompanying financial statement include the account of the company and it wholly and majority owned subsidiary all material intercompany account and transaction have been eliminated the company account for investment in business using the equity method when it ha the ability to exercise significant influence but not control generally between and ownership is not the primary beneficiary and ha not elected the fair value option at december and the company had such investment with carrying amount of million and million respectively the company ha elected the fair value option of accounting for certain of it investment with readily determinable fair value that would otherwise be accounted for under the equity method at december and the fair value of such investment wa million and million respectively redeemable noncontrolling interestthe company owns of it consolidated subsidiary ppd snbl the ownership interest held by third party is classified redeemable noncontrolling interest on the consolidated balance sheet due to certain put option under which the third party may require the company to purchase the remaining ownership interest at premium upon the occurrence of certain event presentationcertain reclassification of prior year amount have been made to conform to the current year presentation revenue recognitionconsumables revenue consist of single use product and are recognized at point in time following the transfer of control of such product to the customer which generally occurs upon shipment instrument revenue typically consist of longer lived asset that for the substantial majority of sale are recognized at point in time in manner similar to consumables service revenue primarily clinical research pharmaceutical and instrument and enterprise service are recognized over time customer receive and consume the benefit of such service for revenue recognized over time the company generally us cost accumulated relative to total estimated cost to measure progress this method approximates satisfaction of the performance obligation for contract that contain multiple performance obligation the company allocates the consideration to which it expects to be entitled the transaction price to each performance obligation based on relative standalone selling price and recognizes the related revenue when or control of each individual performance obligation is transferred to customer the company exercise judgment in determining the timing of revenue by analyzing the point in time or the period over which the customer ha the ability to direct the use of and obtain substantially all of the remaining benefit of the asset the company immediately expense contract cost that would otherwise be capitalized and amortized over period of le than one year change to the scope of service contract generally also include change in the transaction price typically these contract modification are not distinct from existing service provided under the contract and result in cumulative adjustment to revenue on the modification date payment from customer for most instrument and consumables are typically due in fixed number of day after shipment or delivery of the product service arrangement commonly call for payment in advance of performing the work extended service contract upon completion of the service pharmaceutical service or mix of both some arrangement include variable amount of consideration that arise from discount rebate and other program and practice in such arrangement the company estimate the amount by which to reduce the stated contract amount to reflect the transaction price the company record reimbursement for third party pas through and out of pocket cost revenue and the related expense cost of revenue fisher scientific inc note to consolidated financial statement continued contract related balancesaccounts receivable include unconditional right to consideration from customer which generally represent billing that do not bear interest the company maintains allowance for doubtful account for estimate of expected loss resulting from the inability of it customer to pay amount due the allowance for doubtful account is the company best estimate of the amount of probable credit loss in existing account receivable the company determines the allowance based on history of similarly aged receivables the creditworthiness of the customer reason for delinquency current economic condition expectation associated with future event and circumstance where reasonable and supportable forecast are available and any other information that is relevant to the judgment receivables from academic and government customer well large well capitalized commercial customer have historically experienced le collectability risk account balance are charged against the allowance when the company belief it is probable the receivable will not be recovered the company doe not have any off balance sheet credit exposure related to customer contract asset include revenue recognized in advance of billing where the company right to bill includes something other than the passage of time such amount are recorded net of estimated loss resulting from the inability to invoice customer which is primarily due to risk associated with the company performance contract asset are classified current or noncurrent based on the amount of time expected to lapse the company right to consideration becomes unconditional contract liability include billing in excess of revenue recognized such those resulting from customer advance and deposit and unearned revenue on service contract contract liability are classified current or noncurrent based on the period over which remaining performance obligation are expected to be transferred to customer contract asset and liability are presented on net basis in the consolidated balance sheet if they arise from different performance obligation in the contract warranty obligationsthe company provides for the estimated cost of standard product warranty primarily from historical information in cost of product revenue at the time product revenue are recognized the liability for warranty is included in other accrued expense in the accompanying balance sheet extended warranty agreement are considered service contract which are discussed above cost of service contract are recognized incurred lease operating lease that have commenced are included in other asset other accrued expense and other long term liability in the consolidated balance sheet finance lease that have commenced are included in property plant and equipment net current maturity of long term obligation and long term obligation in the consolidated balance sheet classification of lease liability either current or noncurrent is based on the expected timing of payment due under the company obligation right of use rou asset represent the company right to use an underlying asset for the lease term and lease liability represent the company obligation to make lease payment arising from the lease lease rou asset and liability are recognized at the lease commencement date based on the present value of lease payment over the lease term lease with an initial term of month or le are not recorded on the consolidated balance sheet the company recognizes operating lease expense on straight line basis over the lease term finance lease expense includes depreciation which is recognized on straight line basis over the expected life of the leased asset and an immaterial amount of interest expense because most of the company lease do not provide an implicit interest rate the company estimate incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payment the company us the implicit rate when readily determinable lease term include the effect of option to extend or terminate the lease when it is reasonably certain that the company will exercise that option operating lease expense is recognized on straight line basis over the lease term lessee the company account for the lease and non lease component single lease component research and developmentthe company conduct research and development activity to increase it depth of capability in technology software and service research and development cost include employee compensation and benefit consultant facility related cost material cost depreciation and travel research and development cost are expensed incurred restructuring costsaccounting for the timing and amount of termination benefit provided by the company to employee is determined based on whether the company ha substantive plan to provide such benefit the company ha written employment fisher scientific inc note to consolidated financial statement continued contract with the affected employee that includes provision for such benefit the termination benefit are due to the occurrence of an event specified in an existing plan or agreement or the termination benefit are one time benefit in certain circumstance employee termination benefit may meet more than one of the characteristic listed above and therefore may have individual element that are subject to different accounting model from time to time when executing restructuring or exit plan the company also incurs cost other than termination benefit such lease termination cost that are not associated with or will not be incurred to generate revenue these include cost that represent amount under contractual obligation that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic benefit or result in penalty to cancel contractual obligation such cost are recognized when incurred which generally occurs at the contract termination or over the period from when plan to abandon leased facility is approved through the cease use date but charge may continue over the remainder of the original contractual period income taxesthe company recognizes deferred income tax based on the expected future tax consequence of difference between the financial statement basis and the tax basis of asset and liability calculated using enacted tax rate in effect for the year in which the difference are expected to be reflected in the tax return valuation allowance is provided for tax asset that will more likely than not go unused the financial statement reflect expected future tax consequence of uncertain tax position that the company ha taken or expects to take on tax return presuming the taxing authority full knowledge of the position and all relevant fact but without discounting for the time value of money earnings per sharebasic earnings per share ha been computed by dividing net income attributable to thermo fisher scientific inc by the weighted average number of share outstanding during the year except where the result would be antidilutive to net income attributable to thermo fisher scientific inc diluted earnings per share ha been computed using the treasury stock method for outstanding stock option and restricted unit cash and cash equivalentscash equivalent consists principally of money market fund commercial paper and other marketable security purchased with an original maturity of three month or le these investment are carried at cost which approximates market value inventoriesinventories are valued at the lower of cost or net realizable value cost being determined by the first in first out fifo method discussed below prior to the third quarter of certain of the company business utilized the last in first out lifo method the company periodically review quantity of inventory on hand and compare these amount to the expected use of each product or product line in addition the company ha certain inventory that is subject to fluctuating market pricing the company record charge to cost of sale for the amount required to reduce the carrying value of inventory to net realizable value cost associated with the procurement of inventory such inbound freight charge purchasing and receiving cost and internal transfer cost are included in cost of revenue in the accompanying statement of income the component of inventory are follows december december in million material work in finished inventory prior to the third quarter of certain of the company business utilized the lifo method of accounting for inventory during the third quarter of these business which comprised approximately of consolidated inventory changed from the lifo method to the fifo method the company belief this change is preferable it will provide consistent uniform costing method for all inventory across the company better reflect the current value of inventory and improve comparability with peer prior financial statement have not been retrospectively adjusted due to immateriality the cumulative pre tax effect of this change in accounting principle of million wa recorded an increase to inventory and decrease to cost of product revenue in the third quarter of this change wa recorded in the laboratory product and fisher scientific inc note to consolidated financial statement continued biopharma service million and specialty diagnostics million segment reduction to cost of revenue result of the liquidation of lifo inventory were nominal during and the first half of property plant and equipmentproperty plant and equipment are recorded at cost the cost of addition and improvement are capitalized while maintenance and repair are charged to expense incurred the company generally provides for depreciation and amortization using the straight line method over the estimated useful life of the property follows building and improvement to year machinery and equipment including software to year and leasehold improvement the shorter of the term of the lease or the life of the asset when asset are retired or otherwise disposed of the asset and related accumulated depreciation are eliminated from the account and the resulting gain or loss is reflected in the accompanying statement of income property plant and equipment consists of the following december december in million building and machinery equipment and leasehold construction in property plant and equipment at le accumulated depreciation and property plant and equipment net acquisition related intangible assetsacquisition related intangible asset include the cost of acquired customer relationship product technology tradenames backlog and other specifically identifiable intangible asset and are being amortized using the straight line method over their estimated useful life which range up to year the company review these intangible asset for impairment when indication of potential impairment exists such significant reduction in cash flow associated with the asset when impairment indicator exist the company determines whether the carrying value of it intangible asset exceeds the related undiscounted cash flow in these situation the carrying value is written to fair value in addition the company ha tradenames and in process research and development that have indefinite life and which are not amortized intangible asset with indefinite life are reviewed for impairment annually or whenever event or change in circumstance indicate they may be impaired the company may perform an optional qualitative assessment if the company determines that the fair value of the indefinite lived intangible asset is more likely than not greater than it carrying amount no additional testing is necessary if not or if the company bypass the optional qualitative assessment it writes the carrying value down to the fair value if applicable acquisition related intangible asset are follows balance at december at december in million grossaccumulated amortizationnetgrossaccumulated amortizationnetdefinite lived customer relationship product indefinite lived acquisition related intangible asset fisher scientific inc note to consolidated financial statement continued the estimated future amortization expense of acquisition related intangible asset with definite life of december is follows in million and estimated future amortization expense of definite lived intangible asset other assetsother asset in the accompanying balance sheet include operating lease right of use asset investment deferred tax asset pension asset cash surrender value of life insurance insurance recovery receivables related to product liability matter certain intangible asset and other asset at december and the company had million and million respectively of intangible asset not derived from acquisition net of accumulated amortization which are being amortized using the straight line method over their estimated useful life which range up to year equity investment that do not have readily determinable fair value and are not eligible for the net asset value nav practical expedient are measured at cost minus impairment if any plus or minus change resulting from observable price change in orderly transaction for the identical or similar investment of the same issuer the company performs qualitative assessment to identify impairment of these investment at december and the company had such investment with carrying amount of million and million respectively and investment measured at nav of million and million respectively which are included in other asset goodwillthe company ass goodwill for impairment at the reporting unit level annually and whenever event occur or circumstance change that would more likely than not reduce the fair value of reporting unit below it carrying amount such event or circumstance generally include the occurrence of operating loss or significant decline in earnings associated with one or more of the company reporting unit the company is permitted to first ass qualitative factor to determine whether the quantitative goodwill impairment test is necessary if the qualitative assessment result in determination that the fair value of reporting unit is more likely than not le than it carrying amount the company performs quantitative goodwill impairment test the company may bypass the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test the company estimate the fair value of it reporting unit by using forecast of discounted future cash flow and peer market multiple the company would record an impairment charge based on the excess of reporting unit carrying amount over it fair value limited to the amount of goodwill the company determined that no impairment existed in or the change in the carrying amount of goodwill by segment are follows in million life sciencessolutionsanalyticalinstrumentsspecialtydiagnosticslaboratoryproducts andbiopharma servicestotalbalance at december currency translation balance at december acquisition finalization of purchase price allocation for currency translation balance at december fisher scientific inc note to consolidated financial statement continued loss contingenciesaccruals are recorded for various contingency including legal proceeding environmental worker compensation product general and auto liability self insurance and other claim that arise in the normal course of business the accrual are based on management judgment historical claim experience the probability of loss and where applicable the consideration of opinion of internal and or external legal counsel and actuarial estimate additionally the company record receivables from third party insurer up to the amount of the loss when recovery ha been determined to be probable certain liability acquired in acquisition have been recorded at readily determinable fair value and such were discounted to present value at the date of acquisition currency translationall asset and liability of the company subsidiary operating in non dollar currency are translated at period end exchange rate resulting translation adjustment are reflected in the accumulated other comprehensive item component of shareholder equity revenue and expense are translated at average exchange rate for the period currency transaction gain are included in the accompanying statement of income and in aggregate were million million and million in and respectively derivative contractsthe company is exposed to certain risk relating to it ongoing business operation including change to interest rate and currency exchange rate the company us derivative instrument primarily to manage currency exchange and interest rate risk the company recognizes derivative instrument either asset or liability and measure those instrument at fair value if derivative is hedge depending on the nature of the hedge change in the fair value of the derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive item until the hedged item is recognized in earnings derivative that are not designated hedge are recorded at fair value through earnings the company us short term forward and option currency exchange contract primarily to hedge certain balance sheet and operational exposure resulting from change in currency exchange rate predominantly intercompany loan and cash balance that are denominated in currency other than the functional currency of the respective operation the currency exchange contract principally hedge transaction denominated in euro british pound sterling singapore dollar japanese yen hong kong dollar czech koruna and swedish krona the company doe not hold or engage in transaction involving derivative instrument for purpose other than risk management cash flow hedge for derivative instrument that are designated and qualify cash flow hedge the gain or loss on the derivative is reported component of other comprehensive item and reclassified into earnings in the same period or period during which the hedged transaction affect earnings and is presented in the same income statement line item the earnings effect of the hedged item fair value hedge for derivative instrument that are designated and qualify fair value hedge the gain or loss on the derivative well the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in earnings net investment hedge the company us foreign currency denominated debt certain foreign denominated payable and cross currency interest rate swap to partially hedge it net investment in foreign operation against adverse movement in exchange rate portion of the company euro denominated senior note certain foreign denominated payable and it cross currency interest rate swap have been designated and are effective economic hedge of part of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument and certain foreign denominated payable and contract fair value change on the cross currency interest rate swap excluding interest accrual are included in currency translation adjustment within other comprehensive item and shareholder equity government assistancefrom time to time the company receives assistance from various governmental agency generally in the form of cash or non income tax credit these program help offset the cost of certain research and development activity facility construction and expansion effort or hiring objective when the company belief that it is probable that it will meet the condition tied to the assistance it offset the associated expense in the consolidated income statement such amount were not material to the consolidated financial statement of and for the year ended december fisher scientific inc note to consolidated financial statement continued use of estimatesthe preparation of financial statement in conformity with generally accepted accounting principle requires management to make estimate and assumption that affect the reported amount of asset and liability disclosure of contingent asset and liability at the date of the financial statement and the reported amount of revenue and expense during the reporting period the company estimate include among others asset reserve requirement well the amount of future cash flow associated with certain asset and business that are used in assessing the risk of impairment risk and uncertainty associated with the ongoing covid global pandemic materially adversely affected certain of the company business in particularly in the analytical instrument segment and to lesser extent some business within the other three segment the negative impact significantly lessened in and the extent and duration of negative impact in the future which may include inflationary pressure and supply chain disruption are uncertain and may require change to estimate actual result could differ from those estimate recent accounting pronouncementsin september the fasb issued new guidance to require entity to disclose information about supplier finance program among other thing the new guidance requires expanded disclosure about key program term payment term and amount outstanding for obligation under these program for each period presented the company will adopt some aspect of this guidance in using retrospective method and other aspect in using prospective method the adoption of this guidance is not expected to have material impact on the company disclosure however the impact in future period will be dependent on the extent of arrangement of this nature entered into by the companyin november the fasb issued new guidance to require entity to disclose information about certain type of government assistance they receive including cash grant and tax credit among other thing the new guidance requires expanded disclosure regarding the qualitative and quantitative characteristic of the nature amount timing and significant term and condition of transaction with government arising from grant or other form of assistance accounted for under contribution model the company adopted this guidance in the fourth quarter of using prospective method the adoption of this guidance did not have material impact on the company disclosure however the impact in future period will be dependent on the extent of future transaction of this nature entered into by the company in october the fasb amended guidance to recognize and measure contract asset and contract liability acquired in business combination generally this new guidance will result in the company recognizing contract asset and contract liability at the same amount recorded by the acquiree the company adopted this guidance in the fourth quarter of retrospectively to all business combination completed in the first three quarter of and prospectively to all future business combination the adoption of this guidance did not have material impact on the company consolidated financial statement for acquisition that closed in and however the impact in future period will be dependent on the contract asset and contract liability acquired in future business combination in july the fasb amended guidance to require lessor to classify lease operating lease if they have certain variable lease payment structure and would have selling loss if they were classified sale type or direct financing lease the company adopted the guidance in the third quarter of using prospective method the adoption of this guidance did not have material impact on the company consolidated financial statement in december the fasb issued new guidance to simplify the accounting for income tax among other thing the new guidance requires the effect of enacted change in tax law or rate to be reflected in the annual effective tax rate computation in the interim period that includes the enactment date the company adopted this guidance in using prospective method the adoption of this guidance did not have material impact on the company consolidated financial statement however the impact in future period will be dependent on the extent of future event or condition that would be affected such enacted change in tax law or rate in june the fasb issued new guidance to require financial asset measured at amortized cost basis such account receivable to be presented at the net amount expected to be collected based on relevant information about past event including historical experience current condition and reasonable and supportable forecast that affect the collectability of the reported amount during and the fasb issued additional guidance and clarification the company adopted the guidance in using modified retrospective method the adoption of this guidance reduced account receivable and retained earnings by million on january note acquisitionsthe company acquisition have historically been made at price above the determined fair value of the acquired identifiable net asset resulting in goodwill primarily due to expectation of the synergy that will be realized by combining fisher scientific inc note to consolidated financial statement continued the business and the benefit that will be gained from the assembled workforce these synergy include the elimination of redundant facility function and staffing use of the company existing commercial infrastructure to expand sale of the acquired business product and service and use of the commercial infrastructure of the acquired business to cost effectively expand sale of company product and service acquisition have been accounted for using the acquisition method of accounting and the acquired company result have been included in the accompanying financial statement from their respective date of acquisition acquisition transaction cost are recorded in selling general and administrative expense incurred january the company acquired within the specialty diagnostics segment the binding site group based provider of specialty diagnostic assay and instrument to improve the diagnosis and management of blood cancer and immune system disorder the acquisition expands the segment portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma the goodwill recorded result of this business combination is not expected to be tax deductible the component of the purchase price and net asset acquired are follows in billion the binding sitepurchase pricecash paid debt cash acquired net asset acquireddefinite lived intangible asset net tangible deferred tax asset liability the weighted average amortization period for definite lived intangible asset is year the preliminary allocation of the purchase price for the acquisition of the binding site is based on estimate of the fair value of the net asset acquired and is subject to adjustment upon finalization largely with respect to acquired intangible asset and the related deferred tax measurement of these item inherently require significant estimate and assumption the company acquired within the analytical instrument segment based developer of fourier transform infrared gas analysis technology january the company acquired within the laboratory product and biopharma service segment the belgium based european viral vector manufacturing business of groupe novasep sa the european viral vector manufacturing business provides manufacturing service for vaccine and therapy to biotechnology company and large biopharma customer the acquisition expands the segment capability for cell and gene vaccine and therapy the goodwill recorded result of this business combination is not tax deductible on february the company acquired within the life science solution segment mesa biotech inc based molecular diagnostic company mesa biotech ha developed and commercialized polymerase chain reaction pcr based rapid point of care testing platform available for detecting infectious disease including covid the acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care the goodwill recorded result of this business combination is not tax deductible on september the company assumed operating responsibility within the laboratory product and biopharma service segment of new state of the art biologics manufacturing facility in lengnau switzerland from csl limited to perform pharma service for csl with capacity to serve other customer well the goodwill recorded result of this business combination is not tax deductible fisher scientific inc note to consolidated financial statement continued on december the company acquired within the laboratory product and biopharma service segment ppd inc based global provider of clinical research service to the pharma and biotech industry the addition of ppd clinical research service enhances our offering to biotech and pharma customer by enabling them to accelerate innovation and increase their productivity within the drug development process the goodwill recorded result of this business combination is not tax deductible on december the company acquired within the life science solution segment peprotech inc based developer and manufacturer of recombinant protein peprotech provides bioscience reagent known recombinant protein including cytokine and growth factor the acquisition expands the segment bioscience offering the goodwill recorded result of this business combination is not tax deductible in addition in the company acquired within the life science solution segment cell sorting technology asset an ireland based life science distributor and developer of digital pcr platform within the analytical instrument segment belgium based developer of micro chip based technology for liquid chromatography column and within the specialty diagnostics segment transplant diagnostics information system provider the component of the purchase price and net asset acquired for acquisition are follows in million ppdpeprotecheuropean viral vector businessmesa biotechlengnau biologics manufacturing facilityotherpurchase pricecash paid fair value of equity award fair value of contingent consideration cash acquired net asset acquiredcurrent asset property plant and definite lived intangible asset customer product technology other contract liability deferred tax asset liability finance lease liability debt assumed other liability assumed redeemable noncontrolling interest during we finalized the allocation of the purchase price for the lengnau biologics manufacturing facility ppd inc and peprotech inc largely with respect to definite lived intangible asset property plant and equipment contract liability fisher scientific inc note to consolidated financial statement continued equity method investment asset retirement obligation defined benefit pension plan assumed contingent consideration and the related deferred tax the adjustment to the income statement recorded during were not material the weighted average amortization period for definite lived intangible asset acquired in are year for customer relationship year for product technology year for tradenames and year for backlog the weighted average amortization period for all definite lived intangible asset acquired in is year unaudited pro forma informationthe following unaudited pro forma information provides the effect of the company acquisition of ppd if the acquisition had occurred on january year ended december december in million net income attributable to thermo fisher scientific inc the historical consolidated financial information of the company and ppd ha been adjusted in the pro forma information to give effect to pro forma event that are directly attributable to the acquisition and related financing arrangement and are factually supportable to reflect the acquisition of ppd if it had occurred on january the unaudited pro forma result include adjustment to reflect among other thing the incremental intangible asset amortization to be incurred based on the preliminary value of each identifiable intangible asset and the interest expense from debt financing obtained to partially fund the cash consideration transferred pro forma adjustment were tax effected at the company historical statutory rate in effect for the respective period the unaudited pro forma amount are not necessarily indicative of the combined result of operation that would have been realized had the acquisition and related financing occurred on the aforementioned date are they meant to be indicative of any anticipated combined result of operation that the company will experience after the transaction in addition the amount do not include any adjustment for action that may be taken following the completion of the transaction such expected cost saving operating synergy or revenue enhancement that may be realized subsequent to the transaction pro forma net income attributable to thermo fisher scientific inc for the year ended december excludes million of transaction cost initial restructuring cost and debt extinguishment cost directly attributable to the ppd acquisition that were included in the determination of net income attributable to thermo fisher scientific inc for that period these item have reduced pro forma net income attributable to thermo fisher scientific inc for the year ended december by million the company result would not have been materially different from it pro forma result had the company other acquisition occurred at the beginning of ppd revenue and loss attributable to thermo fisher scientific inc in subsequent to the acquisition date were million and million respectively the loss includes non recurring transaction and compensation cost the company acquired within the life science solution segment based provider of spectral dye platform for high resolution biology application which will extend the company existing tool for protein and cell analysis application fisher scientific inc note to consolidated financial statement continued note revenue and contract related balance disaggregated revenuesrevenues by type are follows in million consolidated revenue revenue by geographic region based on customer location are follows in million america asia other consolidated revenue each reportable segment earns revenue from consumables instrument and service in north america europe asia pacific and other region see note for revenue by reportable segment and other geographic data remaining performance obligationsthe aggregate amount of the transaction price allocated to the remaining performance obligation for all open customer contract of december wa billion the company will recognize revenue for these performance obligation they are satisfied approximately of which is expected to occur within the next twelve month amount expected to occur thereafter generally relate to contract manufacturing clinical research and extended warranty service agreement which typically have duration of three to five year contract related balancesnoncurrent contract asset and noncurrent contract liability are included within other asset and other long term liability in the accompanying balance sheet respectively contract asset and liability balance are follows december december in million contract asset net noncurrent contract asset current contract noncurrent contract substantially all of the current contract liability balance at december and wa recognized in revenue during and respectively note business segment and geographical information the company financial performance is reported in four segment description of each segment follows life science solution provides an extensive portfolio of reagent instrument and consumables used in biological and medical research discovery and production of new drug and vaccine well diagnosis of infection and disease these product and service are used by customer in pharmaceutical biotechnology agricultural clinical healthcare academic and government market analytical instrument provides broad offering of instrument and the supporting consumables software and service that are used for range of application in the laboratory and in the field these product and service are used by customer in fisher scientific inc note to consolidated financial statement continued pharmaceutical biotechnology academic government environmental and other research and industrial market well the clinical laboratory specialty diagnostics offer wide range of diagnostic test kit reagent culture medium instrument and associated product to serve customer in healthcare clinical pharmaceutical industrial and food safety laboratory our healthcare product are used to increase the speed and accuracy of diagnosis which improves patient care in more cost efficient manner laboratory product and biopharma service offer virtually everything needed for the laboratory our unique combination of self manufactured and sourced product and extensive service offering enables our customer to focus on their core activity and help them to be more efficient productive and cost effective the segment also includes comprehensive offering of outsourced service used by the pharmaceutical and biotech industry for drug development clinical research clinical trial service and commercial drug manufacturing the company management evaluates segment operating performance based on operating income before certain charge credit to cost of revenue and selling general and administrative expense principally associated with acquisition accounting restructuring and other cost income including cost arising from facility consolidation such severance and abandoned lease expense and gain and loss from the sale of real estate and product line well from significant litigation related matter and amortization of acquisition related intangible asset the company us this measure because it help management understand and evaluate the segment core operating result and facilitates comparison of performance for determining compensation business segment information in million science solution analytical specialty laboratory product and biopharma elimination consolidated segment incomelife science analytical specialty laboratory product and biopharma subtotal reportable cost of revenue adjustment selling general and administrative expense adjustment restructuring and other cost amortization of acquisition related intangible asset consolidated operating interest interest expense other income expense consolidated income before tax depreciationlife science solution analytical specialty laboratory product and biopharma consolidated depreciation fisher scientific inc note to consolidated financial statement continued cost of revenue charge included in the above table consist of charge for the sale of inventory revalued at the date of acquisition inventory write down associated with large scale abandonment of product line and accelerated depreciation on fixed asset to estimated salvage value in connection with the consolidation of operation selling general and administrative charge credit included in the above table consist of significant transaction integration cost including reimbursement thereof related to recent terminated acquisition charge credit for change in estimate of contingent acquisition consideration and charge credit related to product liability litigation in million assetslife science solution analytical specialty laboratory product and biopharma corporate other consolidated total asset capital expenditureslife science solution analytical specialty laboratory product and biopharma corporate consolidated capital expenditure corporate asset consist primarily of cash and cash equivalent and property and equipment at the company corporate office geographical information in million united state consolidated revenue long lived asset united state consolidated long lived asset revenue are attributed to country based on customer location includes property plant and equipment net and operating lease rou asset note other income expense in all period other income expense includes currency transaction gain and loss on non operating monetary asset and liability and net periodic pension benefit cost income excluding the service cost component which is included in operating expense on the accompanying statement of income in other income expense includes million of net loss on investment million of net gain on derivative instrument to address certain foreign currency risk million of loss on the early extinguishment of debt note and million of net settlement gain on pension plan in other income expense includes million of loss on the early extinguishment of debt note million of financing cost associated with obtaining bridge financing commitment in connection with the agreement to acquire ppd note offset in part by million of net gain on investment the company had cash outlay of million in associated with obtaining the bridge financing commitment included in other financing activity net in the accompanying statement of cash flow fisher scientific inc note to consolidated financial statement continued in other income expense includes million of financing cost for terminated acquisition primarily for loan commitment fee and entering into hedging contract and million reclassified from accumulated other comprehensive item related to hedge arrangement note offset in part by million of net gain on investment the company had cash outlay of million in associated with obtaining the loan commitment included in other financing activity net in the accompanying statement of cash flow note stock based compensation expense the company ha stock based compensation plan for it key employee director and others these plan permit the grant of variety of stock and stock based award including restricted stock unit stock option or performance based share determined by the compensation committee of the company board of director or for certain non officer grant by the company employee equity committee which consists of it chief executive officer the company generally issue new share of it common stock to satisfy option exercise and restricted unit vesting grant of stock option and restricted unit generally provide that in the event of both change in control of the company and qualifying termination of an option or unit holder employment all option and service based restricted unit award held by the recipient become immediately vested unless an employment or other agreement with the employee provides for different treatment compensation cost is based on the grant date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement eligibility if earlier and is primarily included in selling general and administrative expense stock optionsthe company practice is to grant stock option at fair market value option vest over year with term of year assuming continued employment with certain exception vesting of the option award is contingent upon meeting certain service condition the fair value of most option grant is estimated using the black scholes option pricing model for option grant that require the achievement of both service and market condition lattice model is used to estimate fair value the fair value is then amortized on straight line basis over the requisite service period of the award which is generally the vesting period use of valuation model requires management to make certain assumption with respect to selected model input expected volatility wa calculated based on the historical volatility of the company stock historical data on exercise pattern is the basis for estimating the expected life of an option the risk free interest rate is based on treasury zero coupon issue with remaining term which approximates the expected life assumed at the date of grant the expected annual dividend rate wa calculated by dividing the company annual dividend based on the most recent quarterly dividend rate by the closing stock price on the grant date the compensation expense recognized for all stock based award is net of estimated forfeiture forfeiture are estimated based on an analysis of actual option forfeiture the weighted average assumption used in the black scholes option pricing model are follows stock price risk free interest expected life of option year annual the weighted average per share grant date fair value of option granted during and were and respectively the total intrinsic value of option exercised during the same period wa million million and million respectively the intrinsic value is the difference between the market value of the share on the exercise date and the exercise price of the option fisher scientific inc note to consolidated financial statement continued summary of the company option activity for the year ended december is presented below share in million weighted average exercise priceweighted average remaining contractual term in year aggregate intrinsic value in million outstanding at december exercised canceled expired outstanding at december vested and unvested expected to vest at december exercisable at december of december there wa million of total unrecognized compensation cost related to unvested stock option granted the cost is expected to be recognized through with weighted average amortization period of year restricted share unit awardsawards of restricted unit convert into an equivalent number of share of common stock the award generally vest over year assuming continued employment with some exception vesting of the award is contingent upon meeting certain service condition and may also be contingent upon meeting certain performance and or market condition the fair market value of the award at the time of the grant is amortized to expense over the requisite service period of the award which is generally the vesting period recipient of restricted unit have no voting right but are entitled to accrue dividend equivalent the fair value of service and performance based restricted unit award is determined based on the number of unit granted and the market value of the company share on the grant date for award with market based vesting condition the company us lattice model to estimate the grant date fair value of the award summary of the company restricted unit activity for the year ended december is presented below unit in million weightedaveragegrant datefair valueunvested at december vested forfeited unvested at december the total fair value of share vested during and wa million million and million respectively of december there wa million of total unrecognized compensation cost related to unvested restricted stock unit award the cost is expected to be recognized through with weighted average amortization period of year employee stock purchase plansqualifying employee are eligible to participate in an employee stock purchase plan sponsored by the company share may be purchased under the program at of the fair market value at the end of the purchase period and the share purchased are not subject to holding period share are purchased through payroll deduction of up to of each participating employee qualifying gross wage the company issued million million and million share respectively of it common stock in and under the employee stock purchase plan fisher scientific inc note to consolidated financial statement continued note pension and other postretirement benefit plan saving plan and other defined contribution plansthe company saving and other defined contribution plan cover the majority of the company eligible and certain non employee contribution to the plan are made by both the employee and the company company contribution are based on the level of employee contribution company contribution to these plan are based on formula determined by the company in and the company charged to expense million million and million respectively related to it defined contribution plan defined benefit pension plansemployees of number of the company non and certain subsidiary participate in defined benefit pension plan covering substantially all full time employee at those subsidiary some of the plan are unfunded permitted under the plan and applicable law the company also maintains postretirement healthcare program at several acquired business where certain employee are eligible to participate the liability and cost associated with the company postretirement healthcare program are generally funded on self insured and insured premium basis and are not material for any period presented the company recognizes the funded status of defined benefit pension and other postretirement benefit plan an asset or liability this amount is defined the difference between the fair value of plan asset and the benefit obligation the company is required to recognize component of other comprehensive item net of tax the actuarial gain loss and prior service cost credit that arise but were not previously required to be recognized component of net periodic benefit cost other comprehensive item is adjusted these amount are later recognized in income component of net periodic benefit cost when company with pension plan is acquired any excess of projected benefit obligation over the plan asset is recognized liability and any excess of plan asset over the projected benefit obligation is recognized an asset the recognition of new liability or new asset result in the elimination of previously existing unrecognized net gain or loss and unrecognized prior service cost or credit the company fund annually at minimum the statutorily required minimum amount actuarially determined during and the company made cash contribution of approximately million million and million respectively contribution to the plan included in the following table are estimated at between and million for the following table provides reconciliation of benefit obligation and plan asset of the company domestic and non pension plan domestic pension benefitsnon pension benefit in million benefit obligation change in projected benefit obligationsprojected benefit obligation at beginning of year acquisition service cost interest settlement plan participant contribution actuarial gain loss benefit paid currency translation and other projected benefit obligation at end of year fisher scientific inc note to consolidated financial statement continued domestic pension benefitsnon pension benefit in million in fair value of plan assetsfair value of plan asset at beginning of year acquisition actual return on plan asset employer settlement plan participant contribution benefit paid currency translation and other fair value of plan asset at end of year funded status amount recognized in balance sheetnoncurrent asset current liability noncurrent liability net amount recognized amount recognized in accumulated other comprehensive itemsnet actuarial loss prior service credit net amount recognized for domestic pension plan actuarial gain experienced in were driven by increase in the weighted average discount rate used to determine the projected benefit obligation well difference between actual and expected return on plan asset for certain portion of plan benefit indexed to asset return for non pension plan actuarial gain experienced in were principally driven by increase in the weighted average discount rate used to determine the projected benefit obligation for domestic pension plan actuarial loss experienced in were driven by difference between actual and expected return on plan asset for certain portion of plan benefit indexed to asset return which were partially offset by actuarial gain due to increase in the weighted average discount rate used to determine the projected benefit obligation difference for non pension plan actuarial gain experienced in were principally driven by increase in the weighted average discount rate used to determine the projected benefit obligation the actuarial assumption used to compute the funded status for the plan are based upon information available of december and and are follows domestic pension benefitsnon pension benefit average assumption used to determine projected benefit obligationsdiscount rate for determining benefit interest crediting rate for cash balance average rate of increase in employee compensationn an fisher scientific inc note to consolidated financial statement continued the actuarial assumption used to compute the net periodic pension benefit cost income are based upon information available of the beginning of the year presented in the following table domestic pension benefitsnon pension benefit average assumption used to determine net benefit cost income discount rate service costn an an discount rate interest average rate of increase in employee compensationn an an expected long term rate of return on the discount rate reflects the rate the company would have to pay to purchase high quality investment that would provide cash sufficient to settle it current pension obligation the discount rate is determined based on range of factor including the rate of return on high quality fixed income corporate bond and the related expected duration of the obligation or in certain instance the company ha used hypothetical portfolio of high quality instrument with maturity that mirror the benefit obligation in order to accurately estimate the discount rate relevant to particular plan the company utilizes full yield curve approach in the estimation of these component by applying the specific spot rate along the yield curve used in the determination of the benefit obligation to the relevant projected cash flow the expected long term rate of return on plan asset reflects the average rate of earnings expected on the fund invested or to be invested to provide for the benefit included in the projected benefit obligation in determining the expected long term rate of return on plan asset the company considers the relative weighting of plan asset the historical performance of total plan asset and individual asset class and economic and other indicator of future performance in addition the company may consult with and consider the opinion of financial and other professional in developing appropriate return benchmark asset management objective include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity to meet immediate and future benefit payment requirement the expected rate of compensation increase reflects the long term average rate of salary increase and is based on historic salary increase experience and management expectation of future salary increase the projected benefit obligation and fair value of plan asset for the company qualified and non qualified pension plan with projected benefit obligation in excess of plan asset are follows pension plan in million plan with projected benefit obligation in excess of plan assetsprojected benefit obligation fair value of plan the accumulated benefit obligation and fair value of plan asset for the company qualified and non qualified pension plan with accumulated benefit obligation in excess of plan asset are follows pension plan in million plan with accumulated benefit obligation in excess of plan assetsaccumulated benefit obligation fair value of plan the measurement date used to determine benefit information is december for all plan asset and benefit obligation fisher scientific inc note to consolidated financial statement continued the net periodic pension benefit cost income includes the following component domestic pension benefitsnon pension benefit in million of net benefit cost income service cost interest cost on benefit expected return on plan asset amortization of actuarial net amortization of prior service benefit settlement curtailment loss net periodic benefit cost income expected benefit payment are estimated using the same assumption used in determining the company benefit obligation at december benefit payment will depend on future employment and compensation level average year employed and average life span among other factor and change in any of these factor could significantly affect these estimated future benefit payment estimated future benefit payment during the next five year and in the aggregate for the five fiscal year thereafter are follows in million domestic pension benefitsnon pension benefitsexpected benefit domestic pension plan assetsthe company overall objective is to manage the asset in liability framework where investment are selected that are expected to have similar change in fair value the related liability will have upon change in interest rate the company invests in portfolio of both return seeking and liability hedging asset primarily through the use of institutional collective fund to achieve long term growth and to insulate the funded position from interest rate volatility the strategic asset allocation us combination of risk controlled and index strategy in fixed income and global equity the target allocation for the investment are approximately to fund investing in equity approximately to fund investing in international equity and approximately to fund investing in fixed income security the portfolio maintains enough liquidity at all time to meet the near term benefit payment non pension plan assetsthe company maintains specific plan asset for many of the individual pension plan outside the the investment strategy of each plan ha been uniquely established based on the country specific standard and characteristic of the plan several of the plan have contract with insurance company whereby the market risk of the benefit obligation are borne by the insurance company when asset are held directly in investment generally the objective is to invest in portfolio of diversified asset with variety of fund manager the investment may include equity fund fixed income fund hedge fund multi asset fund alternative investment and derivative fund with the target asset allocation ranging from approximately for equity fund for fixed income fund for multi asset fund and for fund holding derivative the derivative held by the fund are primarily interest rate swap intended to match the movement in the plan liability each plan maintains enough liquidity at all time to meet the near term benefit payment fisher scientific inc note to consolidated financial statement continued the fair value of the company plan asset at december and by asset category are follows december quotedprices inactivemarketssignificantotherobservableinputssignificantunobservableinputsnot subject to leveling in million level level level domestic pension plan assetsu equity fund international equity fixed income money market total domestic pension plan non pension plan assetsequity fund fixed income multi asset derivative insurance cash money market total non pension plan investment measured at the net asset value per share or it equivalent practical expedient have not been classified in the fair value hierarchy december quotedprices inactivemarketssignificantotherobservableinputssignificantunobservableinputsnot subject to leveling in million level level level domestic pension plan assetsu equity fund international equity fixed income money market total domestic pension plan non pension plan assetsequity fund fixed income hedge multi asset derivative alternative insurance cash money market total non pension plan investment measured at the net asset value per share or it equivalent practical expedient have not been classified in the fair value hierarchy the table above present the fair value of the company plan asset in accordance with the fair value hierarchy note certain investment that are measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy the fair value amount of these investment presented in the above table are intended to permit reconciliation of the fair value hierarchy to the amount presented for the total pension plan asset these investment were also redeemable at the balance sheet date or within limited time restriction fisher scientific inc note to consolidated financial statement continued note income taxesthe component of income before provision for income tax are follows in million non income before income tax the component of the provision for income tax are follows in million income tax provisionfederal non deferred income tax provision benefit federal non state provision for income tax the provision for income tax in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate to income before income tax due to the following in million federal income tax provision for income tax at statutory rate increase decrease resulting from foreign rate differential income tax credit global intangible low taxed foreign derived intangible income excess tax benefit from stock option and restricted stock unit provision for reversal of tax reserve net intra entity transfer domestication transaction valuation withholding tax return reassessment and settlement state income tax net of federal other net provision for income tax the company ha operation and taxable presence in approximately country outside the the company effective income tax rate differs from the federal statutory rate each year due to certain operation that are subject to tax incentive state and local tax and foreign tax that are different than the federal statutory rate during the company settled an irs audit relating to the and tax year the company recorded million net tax benefit primarily from this settlement and related impact which resulted in decrease in the company unrecognized tax benefit of million the company recorded million of charge for expired tax credit and other related component of the settlement the company recorded charge of million to establish valuation allowance against fisher scientific inc note to consolidated financial statement continued certain foreign tax credit which the company belief will more likely than not expire unutilized the company also recorded million of additional net unrecognized tax benefit liability related to other tax audit during the company recorded million income tax benefit related to the deferred tax implication of an intra entity transfer of asset also in the company recorded million income tax benefit related to capital loss resulting from certain intra entity transaction during the company settled an irs audit relating to the and tax year the company recorded million net tax benefit primarily from this settlement and related impact which resulted in decrease in the company unrecognized tax benefit of million of which million wa reclassified to income tax payable the company recorded million of charge for expired tax credit and other related component of the settlement the company recorded charge of million to establish valuation allowance against certain foreign tax credit which the company belief will more likely than not expire unutilized in the company recorded million income tax benefit related to domestication transaction involving the transfer of certain non subsidiary to the including interest expense of those subsidiary the company also recorded valuation allowance of million against the amount of interest expense that the company belief will more likely than not go unused the foreign tax credit discussed below are the result of foreign earnings and profit remitted or deemed remitted to the during the reporting year and the treatment of tax paid in the foreign jurisdiction in the year those profit were originally earned in the company implemented foreign tax credit planning in sweden which resulted in million of foreign tax credit with no related incremental income tax expense the company generally receives tax deduction upon the exercise of non qualified stock option by employee or the vesting of restricted stock unit held by employee for the difference between the exercise price and the market price of the underlying common stock on the date of exercise the company us the incremental tax benefit approach for utilization of tax attribute these excess tax benefit reduce the tax provision in and the company tax provision wa reduced by million million and million respectively of such benefit net deferred tax asset liability in the accompanying balance sheet consists of the following in million tax asset liability depreciation and amortization net operating loss and credit reserve and accrued inventory basis deferred research and development and other capitalized unrealized gain loss on hedging instrument other deferred tax liability net before valuation allowance le valuation deferred tax liability net the company estimate the degree to which tax asset and loss and credit carryforwards will result in benefit based on expected profitability by tax jurisdiction and provides valuation allowance for tax asset and loss and credit carryforwards that it belief will more likely than not expire unutilized at december all of the company valuation allowance relates to deferred tax asset primarily net operating loss and disallowed interest expense carryforward for which any subsequently recognized tax benefit will reduce income tax expense fisher scientific inc note to consolidated financial statement continued the change in the valuation allowance are follows year ended december in million balance addition reduction charged to income tax provision addition due to currency translation and other ending balance at december the company had net federal state and non net operating loss carryforwards of million million and billion respectively use of the carryforwards is limited based on the future income of certain subsidiary of the federal net operating loss carryforwards million expire in the year through and the remainder do not expire the state net operating loss carryforwards expire in the year through of the net non net operating loss carryforwards million expire in the year through and the remainder do not expire at december the company had foreign tax credit carryforwards of million and deferred interest carryforwards of million the foreign tax credit carryforwards will expire in the year through while deferred interest carryforwards do not expire federal tax have been recorded on approximately billion of undistributed foreign earnings of december provision ha not been made for certain state income tax or additional non tax that would be due when cash is repatriated to the the company undistributed foreign earnings are intended to be reinvested outside of the indefinitely the determination of the amount of the unrecognized deferred tax liability related to the undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed the company intent is to only make distribution from non subsidiary in the future when they can be made at no net tax cost unrecognized tax benefitsas of december the company had billion of unrecognized tax benefit substantially all of which if recognized would reduce the effective tax rate reconciliation of the beginning and ending amount of unrecognized tax benefit is follows in million balance addition due to addition for tax position of current addition for tax position of prior reduction for tax position of prior year closure of tax year settlement ending balance substantially all of the unrecognized tax benefit are classified long term liability the company doe not expect it unrecognized tax benefit to change significantly over the next twelve month during the company unrecognized tax benefit increased by million result of uncertain tax position relating to foreign tax position and decreased million relating to federal and state tax position which included million from the settlement of the irs audit of the and tax year the company also assumed million of uncertain tax benefit part of the acquisition of ppd during the company unrecognized tax benefit increased by million result of uncertain tax position relating to foreign tax position and decreased million relating to federal and state tax position the company also assumed million of uncertain tax benefit part of the acquisition of ppd during the company unrecognized tax benefit decreased million result of uncertain tax position relating to foreign tax position and million relating to federal and state tax position which included million from the settlement of the irs audit of the and tax year fisher scientific inc note to consolidated financial statement continued the company classified interest and penalty related to unrecognized tax benefit income tax expense the total amount of interest and penalty related to uncertain tax position and recognized in the balance sheet of december and wa million and million respectively the company conduct business globally and result thermo fisher or one or more of it subsidiary file income tax return in the federal jurisdiction and various state and foreign jurisdiction in the normal course of business the company is subject to examination by taxing authority throughout the world including such major jurisdiction australia canada china denmark finland france germany japan singapore sweden the united kingdom and the united state with exception the company is no longer subject to state and local or non income tax examination for year before and no longer subject to federal income tax examination for year before note earnings per share in million except per share amount income attributable to thermo fisher scientific inc basic weighted average plus effect of stock option and restricted stock diluted weighted average basic earnings per share diluted earnings per share antidilutive stock option excluded from diluted weighted average note debt and other financing arrangement effective interest rate at december december december dollar in million floating rate sofr year senior note due floating rate sofr year senior note due year senior note due floating rate euribor year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated floating rate sofr year senior note due year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due yen denominated year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due yen denominated year senior note due year senior note due euro denominated fisher scientific inc note to consolidated financial statement continued effective interest rate at december december december dollar in million year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due year senior note due yen denominated year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due yen denominated year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due euro denominated year senior note due year senior note due euro denominated year senior note due yen denominated year senior note due year senior note due year senior note due euro denominated year senior note due euro denominated year senior note due yen denominated other total borrowing at par unamortized discount unamortized debt issuance cost total borrowing at carrying finance lease le short term obligation and current long term obligation sofr secured overnight financing rateeuribor euro interbank offered ratethe effective interest rate for the fixed rate debt include the stated interest on the note the accretion of any discount premium and the amortization of any debt issuance cost see note for fair value information pertaining to the company long term borrowing fisher scientific inc note to consolidated financial statement continued of december the annual repayment requirement for debt obligation are follows in million borrowingsfinance lease and in addition to available borrowing under the company revolving credit agreement discussed below the company had unused line of credit of million of december these unused line of credit generally provide for short term unsecured borrowing at various interest rate credit facilitiesthe company ha revolving credit facility the facility with bank group that provides for up to billion of unsecured multi currency revolving credit the facility expires on january the revolving credit agreement call for interest at either term sofr euribor based rate for fund drawn in euro or rate based on the prime lending rate of the agent bank at the company option the agreement contains affirmative negative and financial covenant and event of default customary for facility of this type the covenant in the facility include consolidated net interest coverage ratio consolidated ebitda to consolidated net interest expense such term are defined in the facility specifically the company ha agreed that so long any lender ha any commitment under the facility any letter of credit is outstanding under the facility or any loan or other obligation is outstanding under the facility it will maintain minimum consolidated net interest coverage ratio of of the last day of any fiscal quarter of december no borrowing were outstanding under the facility although available capacity wa reduced by immaterial outstanding letter of credit commercial paper programsthe company ha commercial paper program pursuant to which it may issue and sell unsecured short term promissory note cp note under the program maturity may not exceed day from the date of issue and the cp note are issued on private placement basis under customary term in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment under the euro program maturity may not exceed day and may be denominated in euro dollar japanese yen british pound sterling swiss franc canadian dollar or other currency under both program the cp note are issued at discount from par or premium to par in the case of negative interest rate or alternatively are sold at par and bear varying interest rate on fixed or floating basis of december there were billion of outstanding borrowing under these program senior notesinterest is payable quarterly on the floating rate senior note annually on the euro denominated fixed rate senior note and semi annually on all other senior note each of the fixed rate senior note may be redeemed at redemption price of of the principal amount plus specified make whole premium and accrued interest except for the euro denominated floating rate senior note which may not be redeemed early the floating rate senior note may be redeemed in whole or in part on or after their applicable call date at redemption price of of the principal amount plus accrued interest the company is subject to certain affirmative and negative covenant under the indenture governing the senior note the most restrictive of which limit the ability of the company to pledge principal property security under borrowing arrangement the company wa in compliance with all covenant at december in the company completed the full allocation of an amount equal to the net proceeds from the senior note due to finance or refinance in whole or in part certain covid response project in the company redeemed all of it senior note due in connection with the redemption the company incurred million of loss on the early extinguishment of debt included in other income expense on the accompanying statement of income in the company redeemed some of it existing senior note in connection with these redemption the company incurred million of loss on the early extinguishment of debt included in other income expense on the accompanying statement of income upon redemption of the senior note the company terminated the related fixed to floating rate interest rate fisher scientific inc note to consolidated financial statement continued swap arrangement and received million included in other financing activity net in the accompanying statement of cash flow thermo fisher scientific finance thermo fisher international wholly owned finance subsidiary of the company issued each of the floating rate senior note due the senior note due the senior note due the senior note due the senior note due the senior note due and the senior note due included in the table above collectively the euronotes in registered public offering the company ha fully and unconditionally guaranteed all of thermo fisher international obligation under the euronotes and all of thermo fisher international other debt security and no other subsidiary of the company will guarantee these obligation thermo fisher international is finance subsidiary defined in rule vi of the exchange act with no asset or operation other than those related to the issuance administration and repayment of the euronotes and other debt security issued by thermo fisher international from time to time the financial condition result of operation and cash flow of thermo fisher international are consolidated in the financial statement of the company note lease lessee the company lease certain logistics office and manufacturing facility well vehicle copier and other equipment these operating lease generally have remaining lease term between month and year and some include option to extend generally for to year or have option to terminate the arrangement within year the company ha guaranteed the residual value of three leased operating facility with lease term ending in and the company ha agreed with the lessor to comply with certain financial covenant consistent with it other debt arrangement note the aggregate maximum guarantee under these three lease arrangement is million operating lease rou asset and lease liability for these lease arrangement are recorded on the consolidated balance sheet of december but exclude any amount for residual value guarantee lessee the consolidated financial statement include the following relating to operating lease dollar in million of incomeoperating lease cost variable lease statement of cash flowscash used in operating activity for payment of amount included in the measurement of operating lease liability operating lease rou asset obtained in exchange for new operating lease balance sheetrou asset operating lease liability operating lease liability weighted average at end of yearremaining operating lease yearsdiscount rou asset are classified in other asset in the consolidated balance sheet operating lease liability are classified in other accrued expense and other long term liability respectively in the consolidated balance sheet lease cost arising from finance lease short term lease and sublease income are not material see note for additional information relating to finance lease fisher scientific inc note to consolidated financial statement continued of december future payment of operating lease liability are follows in million and total lease le imputed total operating lease liability lessor operating lease sale type lease and direct financing lease are not material note commitment and contingenciespurchase obligationsthe company ha entered into unconditional purchase obligation in the ordinary course of business that include agreement to purchase good service or fixed asset and to pay royalty that are enforceable and legally binding and that specify all significant term including fixed or minimum quantity to be purchased fixed minimum or variable price provision and the approximate timing of the transaction purchase obligation exclude agreement that are cancelable at any time without penalty the aggregate amount of the company unconditional purchase obligation totaled billion at december and the majority of these obligation are expected to be settled during the analytical instrument segment recorded charge to cost of product revenue for million in related to an existing supply contract for component of electron microscopy instrument the agreement requires the company to make future minimum purchase through the company developed and launched an alternative product beginning in and based on the expected demand for the internally developed product the third party product the company doe not expect to use all of the product it will be required to buy resulting in loss on the purchase commitment letter of credit guarantee and other commitmentsoutstanding letter of credit and bank guarantee totaled million at december substantially all of these letter of credit and guarantee expire before outstanding surety bond and other guarantee totaled million at december the expiration of these bond and guarantee range through the letter of credit bank guarantee and surety bond principally secure performance obligation and allow the holder to draw fund up to the face amount of the letter of credit bank guarantee or surety bond if the applicable business unit doe not perform contractually required the company is guarantor of pension plan obligation of divested business the purchaser of the divested business ha agreed to pay for the pension benefit however the company wa required to guarantee payment of these pension benefit should the purchaser fail to do so the amount of the guarantee at december wa million in connection with the sale of business of the company the buyer have assumed certain contractual obligation of such business and have agreed to indemnify the company with respect to those assumed liability in the event third party to transferred contract doe not recognize the transfer of obligation or buyer default on it obligation under the transferred contract the company could be liable to the third party for such obligation however in such event the company would be entitled to seek indemnification from the buyer indemnificationsin conjunction with certain transaction primarily divestiture the company ha agreed to indemnify the other party with respect to certain liability related to the business that were sold or leased property that were abandoned retention of certain environmental tax employee and product liability the scope and duration of such indemnity obligation vary from transaction to transaction where probable an obligation for such indemnification is recorded liability generally fisher scientific inc note to consolidated financial statement continued maximum obligation can not be reasonably estimated other than obligation recorded liability at the time of divestiture historically the company ha not made significant payment for these indemnification in connection with the company effort to reduce the number of facility that it occupies the company ha vacated some of it leased facility or sublet them to third party when the company sublet facility to third party it remains the primary obligor under the master lease agreement with the owner of the facility result if third party vacates the sublet facility the company would be obligated to make lease or other payment under the master lease agreement the company belief that the financial risk of default by sublessors is individually and in the aggregate not material to the company financial position or result of operation in connection with the sale of product in the ordinary course of business the company often make representation affirming among other thing that it product do not infringe on the intellectual property right of others and agrees to indemnify customer against third party claim for such infringement the company ha not been required to make material payment under such provision environmental mattersthe company is currently involved in various stage of investigation and remediation related to environmental matter the company can not predict all potential cost related to environmental remediation matter and the possible impact on future operation given the uncertainty regarding the extent of the required cleanup the complexity and interpretation of applicable law and regulation the varying cost of alternative cleanup method and the extent of the company responsibility expense for environmental remediation matter related to the cost of installing operating and maintaining groundwater treatment system and other remedial activity related to historical environmental contamination at the company domestic and international facility were not material in any period presented the company record accrual for environmental remediation liability based on current interpretation of environmental law and regulation when it is probable that liability ha been incurred and the amount of such liability can be reasonably estimated the company calculates estimate based upon several factor including input from environmental specialist and management knowledge of and experience with these environmental matter the company includes in these estimate potential cost for investigation remediation and operation and maintenance of cleanup site at december the company total environmental liability wa approximately million while management belief the accrual for environmental remediation are adequate based on current estimate of remediation cost the company may be subject to additional remedial or compliance cost due to future event such change in existing law and regulation change in agency direction or enforcement policy development in remediation technology or change in the conduct of the company operation which could have material adverse effect on the company financial position result of operation and cash flow litigation and related contingenciesthe company is involved in various dispute governmental and or regulatory inspection inquiry investigation and proceeding and litigation matter that arise from time to time in the ordinary course of business the dispute and litigation matter include product liability intellectual property employment and commercial issue the company determines the probability and range of possible loss based on the current status of each of these matter liability is recorded in the financial statement if it is believed to be probable that loss ha been incurred and the amount of the loss can be reasonably estimated the company establishes liability that is an estimate of amount expected to be paid in the future for event that have already occurred the company accrues the most likely amount or at least the minimum of the range of probable loss when range of probable loss can be estimated the accrued liability are based on management judgment to the probability of loss for asserted and unasserted claim and where applicable actuarially determined estimate accrual estimate are adjusted additional information becomes known or payment are made the amount of ultimate loss may differ from these estimate due to the inherent uncertainty associated with pending litigation or claim the company can not predict the outcome nor with respect to certain pending litigation or claim where no liability ha been accrued make meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome the company ha no material accrual for pending litigation or claim for which accrual amount are not disclosed below nor are material loss deemed probable for such matter it is reasonably possible however that an unfavorable outcome that exceeds the company current accrual estimate if any for one or more of the matter described below could have material adverse effect on the company result of operation financial position and cash flow product liability worker compensation and other personal injury mattersthe company is involved in various proceeding and litigation that arise from time to time in connection with product liability worker compensation and other personal injury matter the range of probable loss for product liability worker compensation and other personal injury matter of the company continuing operation at december wa fisher scientific inc note to consolidated financial statement continued approximately million to million on an undiscounted basis the portion of these liability assumed in the merger with fisher wa recorded at it fair present value at the date of merger the company accrual for all such matter in total including the discounted liability wa million at december or million undiscounted the accrual includes estimated defense cost and is gross of estimated amount due from insurer of million at december or million undiscounted that are included in other asset in the accompanying balance sheet the portion of these insurance asset assumed in the merger with fisher wa also recorded at it fair value at the date of merger in addition to the above accrual of december the company had product liability accrual of million undiscounted relating to divested business although the company belief that the amount accrued and estimated recovery are probable and appropriate based on available information including actuarial study of loss estimate the process of estimating loss and insurance recovery involves considerable degree of judgment by management and the ultimate amount could vary which could have material adverse effect on the company result of operation financial position and cash flow insurance contract do not relieve the company of it primary obligation with respect to any loss incurred the collectability of amount due from it insurer is subject to the solvency and willingness of the insurer to pay well the legal sufficiency of the insurance claim management monitor the payment history well the financial condition and rating of it insurer on an ongoing basis note comprehensive income and shareholder equity comprehensive income loss change in each component of accumulated other comprehensive item net of tax are follows in million currencytranslationadjustmentunrealizedlosses onhedginginstrumentspension andotherpostretirementbenefitliabilityadjustmenttotalbalance at december other comprehensive item before reclassification amount reclassified from accumulated other comprehensive net other comprehensive item balance at december shareholder equityat december the company had reserved million unissued share of it common stock for possible issuance under stock based compensation plan early in the first quarter of the company repurchased billion of the company common stock million share note fair value measurement and fair value of financial instrumentsfair value measurementsthe company us the market approach technique to value it financial instrument and there were no change in valuation technique during the company financial asset and liability carried at fair value are primarily comprised of investment in publicly traded security insurance contract investment in derivative contract mutual fund holding publicly traded security and other investment in unit trust held asset to satisfy outstanding deferred compensation and retirement liability and acquisition related contingent consideration asset and liability carried at fair value are classified and disclosed in one of the following three category level quoted market price in active market for identical asset or liability that the company ha the ability to access level observable market based input or unobservable input that are corroborated by market data such quoted price interest rate and yield curve level input are unobservable data point that are not corroborated by market data fisher scientific inc note to consolidated financial statement continued the following table present information about the company financial asset and liability measured at fair value on recurring basis december quotedprices inactivemarketssignificantotherobservableinputssignificantunobservableinputs in million level level level assetscash equivalent insurance derivative total asset liabilitiesderivative contract contingent total liability december quotedprices inactivemarketssignificantotherobservableinputssignificantunobservableinputs in million level level level assetscash equivalent insurance derivative total asset liabilitiesderivative contract contingent total liability the company us the black scholes model to value it warrant the company determines the fair value of it insurance contract by obtaining the cash surrender value of the contract from the issuer the fair value of derivative contract is the estimated amount that the company would receive pay upon liquidation of the contract taking into account the change in interest rate and currency exchange rate the company initially measure the fair value of acquisition related contingent consideration based on amount expected to be transferred probability weighted discounted to present value change to the fair value of contingent consideration are recorded in selling general and administrative expense the following table provides rollforward of the fair value determined by level input such likelihood of achieving production or revenue milestone well change in the fair value of the investment underlying recapitalization investment portfolio of the contingent consideration fisher scientific inc note to consolidated financial statement continued in million considerationbeginning balance acquisition including assumed balance payment change in fair value included in earnings ending balance derivative contractsthe following table provides the aggregate notional value of outstanding derivative contract december december in million amountcross currency interest rate swap designated net investment hedge currency exchange while certain derivative are subject to netting arrangement with counterparties the company doe not offset derivative asset and liability within the balance sheet the following table present the fair value of derivative instrument in the accompanying balance sheet and statement of income fair value assetsfair value liability december december december december in million designated hedging instrumentscross currency interest rate swap derivative not designated hedging instrumentscurrency exchange contract total derivative the fair value of the cross currency interest rate swap is included in the accompanying balance sheet under the caption other asset or other long term liability the fair value of the currency exchange contract is included in the accompanying balance sheet under the caption other current asset or other accrued expense gain loss recognized in million value hedging relationshipscross currency interest rate swapshedged long term obligation included in other income expense derivative designated hedging instrument included in other income expense interest rate swapshedged long term obligation included in other income expense derivative designated hedging instrument included in other income expense derivative designated cash flow hedgesinterest rate swapsamount reclassified from accumulated other comprehensive item to other income expense fisher scientific inc note to consolidated financial statement continued gain loss recognized in million instrument designated net investment hedgesforeign currency denominated debt and other payablesincluded in currency translation adjustment within other comprehensive cross currency interest rate swapsincluded in currency translation adjustment within other comprehensive included in other income expense derivative not designated hedging instrumentscurrency exchange contractsincluded in cost of product included in other income expense gain and loss recognized on currency exchange contract and the interest rate swap designated fair value hedge are included in the accompanying statement of income together with the corresponding offsetting loss and gain on the underlying hedged transaction the company us foreign currency denominated debt certain foreign denominated payable and cross currency interest rate swap to partially hedge it net investment in foreign operation against adverse movement in exchange rate portion of the company euro denominated senior note certain foreign denominated payable and it cross currency interest rate swap have been designated and are effective economic hedge of part of the net investment in foreign operation accordingly foreign currency transaction gain or loss due to spot rate fluctuation on the euro denominated debt instrument and certain foreign denominated payable and contract fair value change on the cross currency interest rate swap excluding interest accrual are included in currency translation adjustment within other comprehensive item and shareholder equity see note and note for additional information on the company risk management objective and strategy cash flow hedge arrangement in the company entered into interest rate swap arrangement to mitigate the risk of interest rate rising prior to completion of debt offering based on the company conclusion that the debt offering were probable the swap hedged the cash flow risk for each of the interest payment on the planned fixed rate debt issue the aggregate fair value of the terminated hedge net of tax ha been classified reduction to accumulated other comprehensive item and will be amortized to interest expense over the term of the related debt issuance the company had cash outlay aggregating million in associated with termination of the arrangement included in other financing activity net in the accompanying statement of cash flow in late the company determined that the previously anticipated debt offering were probable of not occurring and reclassified million from accumulated other comprehensive item to other income expense during in connection with the extinguishment of debt note the company reclassified million from accumulated other comprehensive item to other income expense fair value of other financial instrumentsthe carrying value and fair value of the company debt instrument are follows december in million valuevaluevaluevaluesenior note commercial the fair value of debt instrument wa determined based on quoted market price and on borrowing rate available to the company at the respective period end which represent level measurement fisher scientific inc note to consolidated financial statement continued note supplemental cash flow information in million paid for interest income non cash investing and financing activitiesacquired but unpaid property plant and fair value of equity award exchanged fair value of acquisition contingent consideration finance lease rou asset obtained in exchange for new finance lease declared but unpaid issuance of stock upon vesting of restricted stock cash cash equivalent and restricted cash is included in the consolidated balance sheet follows december december in million and cash equivalent restricted cash included in other current restricted cash included in other cash cash equivalent and restricted cash amount included in restricted cash primarily represent fund held collateral for bank guarantee and incoming cash in china awaiting government administrative clearance note restructuring and other cost restructuring and other cost in primarily included impairment of long lived asset and continuing charge for headcount reduction and facility consolidation in an effort to streamline operation in severance action associated with facility consolidation and cost reduction measure affected le than of the company workforce restructuring and other cost in primarily included charge for impairment of an acquired technology asset and tradename asset and to lesser extent compensation due to employee at acquired business on the date of acquisition in severance action associated with facility consolidation and cost reduction measure affected le than of the company workforce restructuring and other cost in primarily included continuing charge for headcount reduction and facility consolidation in an effort to streamline operation and charge for the write off of acquired technology in severance action associated with facility consolidation and cost reduction measure affected approximately of the company workforce of february the company ha identified restructuring action that will result in additional charge of approximately million primarily in and expects to identify additional action in future period which will be recorded when specified criterion are met such communication of benefit arrangement or when the cost have been incurred fisher scientific inc note to consolidated financial statement continued restructuring and other cost by segment are follows in million science solution analytical specialty laboratory product and biopharma the following table summarizes the change in the company accrued restructuring balance other amount reported restructuring and other cost in the accompanying statement of income have been summarized in the note to the table accrued restructuring cost are included in other accrued expense in the accompanying balance sheet in million total balance at december net restructuring charge incurred in payment currency translation balance at december net restructuring charge incurred in payment currency translation balance at december net restructuring charge incurred in payment balance at december the movement in the restructuring liability principally consist of severance and other cost such relocation and moving expense associated with facility consolidation well employee retention cost which are accrued ratably over the period through which employee must work to qualify for payment excludes million of charge principally million for impairment of acquired technology in the life science solution segment resulting from reduction in expected cash flow and to lesser extent charge across the company segment for fixed asset writedowns and cost associated with environmental remediation at abandoned previously owned facility excludes million of charge principally million for impairment of an acquired technology asset and tradename asset in the life science solution and laboratory product and biopharma service segment principally resulting from reduction in expected cash flow and million of charge for compensation contractually due to employee of acquired business at the date of acquisition in the life science solution and laboratory product and biopharma service segment excludes million of net charge primarily charge for impairment of long lived asset in the specialty diagnostic segment the company expects to pay accrued restructuring cost primarily through